Efficacy Comparison of Ivermectin 1% Topi[INVESTIGATOR_326961] 40 mg Modified Release 
(MR) 
Capsules Versus Ivermectin 1% Topi[INVESTIGATOR_326962].
Study ID: [REMOVED] 
Date: 10 Feb 2017
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.113322  
version Final dated 10-FEB-2017 
Page 1 of 106 CONFIDENTIAL 
CLINICAL TRIAL PROTOCOL  
PROTOCOL NUMBER: RD.03.SPR. 113322  
CONFIDENTIAL 
This document contains confidential, proprietary information 
All the information provided to the Investigator and his/her staff and all data obtained through 
this GALDERMA R&D clinical trial protocol are confidential.  The Sponsor reserves all 
proprietary rights. No information may be disclosed to any third party without prior written 
consent from GALDERMA R&D. 
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.113322  
version Final dated 10-FEB-2017 
Page 2 of 106 CONFIDENTIAL 
TITLE PAGE 
Title: Efficacy comparison of Ivermectin 1% topi[INVESTIGATOR_326963] 
40 mg Modified release (MR) capsules  versus Ivermectin 1% topi[INVESTIGATOR_326964].  
 
Project Name:  [CONTACT_327075]:  Clinical Trial Phase:  
Ivermectin 1% cream and  
Doxycycline [ADDRESS_403541] NUMBER: 2017- 000157- 40  
IND NUMBER: 076064 (Ivermectin 1% cream); 067833 (Doxycycline 40mg MR capsules) 
 
Version Number: Final - [ADDRESS_403542] details :  
Name  [CONTACT_154500] R&D  
Address  Les Templiers  
2400, Route des Colles  
[ZIP_CODE] Biot - [LOCATION_009]  
Tel [PHONE_6835].47.68  
Fax [PHONE_6835].71.[ADDRESS_403543] 
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.113322  
version Final dated 10-FEB-2017 
Page 3 of 106 CONFIDENTIAL 
details provided in Section 8.2.2  
This clinical trial will be performed in compliance with applicable regulations, Good Clinical 
Practice (GCP) and the ethical principles that have their origin in the Declaration of Helsinki. 
This clinical trial Protocol follows g uidelines outlined by [CONTACT_175416] (ICH) and the GALDERMA R&D Phase IV department template . 
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.113322  
version Final dated 10-FEB-2017 
Page 4 of 106 CONFIDENTIAL 
CLINICAL TRIAL ADMINISTRATIVE STRUCTURE  
The following table contains the details of GALDERMA R&D employees involved in the conduc t 
of the trial.  
SPONSOR PERSONNEL  
Name/Title  Affiliation/Address/Tel./Fax  Responsibilities  
 
 GALDERMA R&D SNC,  
 
 
 
 
 
 Responsible for clinical 
management and 
monitoring of clinical trial 
and for overall coordination 
of clinical project  
 
 Galderma R&D, SNC  
Same as above  
 
 
 Responsible for  
administrative follow -up and 
management of Trial Master 
File 
 
 
 
  Galderma R&D, SNC  
Same as above  
  
 
  Responsible for study  
medical management and 
safety surveillance  

GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.113322  
version Final dated 10-FEB-2017 
Page 5 of 106 CONFIDENTIAL 
 
 
 GALDERMA R&D SNC,  
Same as above  
 
 
 Responsible for the Phase 
IV group  
 
 GALDERMA R&D SNC,  
Same as above  
 
 
 Responsible for the coordination 
of all data management activities  
 
 GALDERMA R&D SNC,  
Same as above  
 
 
 Responsible for the management 
of all statistical activities  
 
 GALDERMA R&D SNC,  
Same as above  
 
 
 Responsible for quality assurance 
and audits  

GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.113322  
version Final dated 10-FEB-2017 
Page 6 of 106 CONFIDENTIAL 
 
 GALDERMA R&D SNC,  
Same as above  
 
 
 Responsible for the 
management of all clinical 
supplies activities  
 
 GALDERMA R&D SNC,  
Same as above  
 
 
 Responsible for safety 
surveillance  
 

GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.113322  
version Final dated 10-FEB-2017 
Page 7 of 106 CONFIDENTIAL 
SIGNATURE [CONTACT_327076] ’s Agreement 
I agree to: 
 Implement and conduct this clinical trial diligently and in strict compliance with the protocol, 
Good Clinical Practices and all applicable laws and regulations. 
 Accurately record all required data on each patient ’s electronic Case Report Forms 
(eCRFs) in a timely manner on an ongoing basis. 
 Use the investigational product(s) for this clinical trial only. Maintain a complete and 
accurate inventory during and at the completion of the clinical trial. Maintain records of all 
investigational product units received, dispensed, returned by [CONTACT_748], and the 
number of product units returned to GALDERMA R&D . 
 Allow authorised representatives of GALDERMA R&D  or regulatory authorities to conduct 
on-site visits to review, audit, and copy clinical trial documents. I will personally meet these 
representatives at mutually convenient times to answer any clinical trial-related questions. 
 Comply strictly with the agreement signed for the carrying out of my services within the 
scope of this protocol, especially with the provisions regarding confidentiality and 
intellectual property (results and publications). 
I have read this protocol in its entirety, including the above statement, and I agree to all aspects. 
PRINCIPAL INVESTIGATOR   
[INVESTIGATOR_326965]:  
SIGNATURE [CONTACT_327077] R&D    
MEDICAL EXPERT  
[INVESTIGATOR_326965]: 
   

GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.113322  
version Final dated 10-FEB-2017 
Page 8 of 106 CONFIDENTIAL 
 
SPONSOR REPRESENTATIV E 
PRINTED NAME: 
   
[CONTACT_327078] S IGNED COPY TO GALDERMA  R&D  AND KEEP A COPY AT Y OUR SITE  

GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.113322  
version Final dated 10-FEB-2017 
Page 9 of 106 CONFIDENTIAL 
DISTRIBUTION 
Copy of the Protocol: 
All signatories and, 
 , GALDERMA R&D   
 , GALDERMA R&D  
  , GALDERMA R&D  
  , GALDERMA R&D  
   , GALDERMA R&D  
  , GALDERMA R&D  
  , Galderma R&D  
  , Galderma R&D  
  GALDERMA R&D   
  Product Development Coordination 
& Expertise Group GALDERMA R&D  
 , Galderma R&D  
  GALDERMA International  
  , GALDERMA R&D  
  , GALDERMA International  
  Regulatory Affairs, Galderma Laboratories, L.P. 
[LOCATION_003] 
  Prescription Business Unit, Galderma Laboratories, 

GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.113322  
version Final dated 10-FEB-2017 
Page 10 of 106 CONFIDENTIAL 
L.P. [LOCATION_003] 
 , Galderma Laboratories, 
L.P. [LOCATION_003].  
 
 , Regulatory, Medical & Technical Affairs, Galderma 
Canada  
 , Galderma [LOCATION_013]  
 
Copy of the Synopsis: 
  , GALDERMA International  
 , GALDERMA 
International   
 , GALDERMA International   
 , GALDERMA Poland  
 , GALDERMA Ceska & Slovenska  
Original Protocol: 
Archives (GALDERMA R&D Sophia Antipolis) 

GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.[ADDRESS_403544] profile  ............................................................................................. 31 
2.3 Risk/Benefit assessment  ....................................................................................................... 31 
3. CLINICAL TRIAL OBJECTIVES AND CLINICAL HYPOTHESIS  ......................................... 31 
3.1 Clinical trials objectives  ......................................................................................................... 3 1 
3.2 Clinical hypothesis  .................................................................................................................. 31 
4. SELECTION AND DISPOSITION OF CLINICAL TRIAL POPULATION  .............................. 32 
4.1 Number of subjects  ................................................................................................................. 32 
4.2 Clinical trial population  .......................................................................................................... 32 
 Inclusion criteria  ................................................................................................................. 32  4.2.1
 Exclusion criteria  ................................................................................................................ 33  4.2.2
4.3 Prior and concomitant therapi[INVESTIGATOR_014]  ......................................................................................... 36 
 Definition  ............................................................................................................................... 36  4.3.1
 Categories  ............................................................................................................................. 36  4.3.2
 Recording  ............................................................................................................................. 36  4.3.3
 Authorised therapi[INVESTIGATOR_326966].  ............................................................. 37  4.3.4
 Prohibited therapi[INVESTIGATOR_326966]  ............................................................... 37  4.3.5
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.113322  
version Final dated 10-FEB-2017 
Page 12 of 106 CONFIDENTIAL 
4.4 Procedures / reasons for discontinuation ......................................................................... 38 
5. INVESTIGATIONAL PLAN  ........................................................................................................... 40 
5.1 Overall clinical trial design  .................................................................................................... 40 
5.2 Discussion of clinical trial design  ....................................................................................... 40 
5.3 Clinical trial duration and termination  ................................................................................ 41 
5.4 Clinical trial flow chart  ............................................................................................................ 42 
5.5 Clinical trial visit description and procedures ................................................................. 43 
 Visit 1 – Screening/Baseline visit  ................................................................................... 43  5.5.1
 Visit 2 and 3 – Week 4 and Week 8  ................................................................ ................. 45  5.5.2
 Visit 4- Week 12 / Last clinical trial visit  ....................................................................... [ADDRESS_403545] Identification Number (SIN)  ................................................................ .............. [ADDRESS_403546] ................................................................................... 54  6.4.5
6.5 Blinding  ...................................................................................................................................... 55 
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.113322  
version Final dated 10-FEB-2017 
Page 13 of 106 CONFIDENTIAL 
 Verification of blinding  ...................................................................................................... 55  6.5.1
 Unblinding during the clinical trial  ................................................................ ................. 55  6.5.2
7. EFFICACY AND SAFETY ASSESSMENT  ................................................................................ 56 
7.1 Efficacy assessments  ............................................................................................................. 56 
 Inflammatory Lesion Count  .............................................................................................. 56  7.1.1
 Clinician’s Erythema Assessment (CEA)  ..................................................................... 56  7.1.2
 Investigator’s Global Assessment (IGA)  ...................................................................... 57  7.1.3
 Stinging/Burning sensation  ............................................................................................. [ADDRESS_403547]’s Global Improvement in Rosacea  .................................................................. 60  7.1.7
7.2 Safety assessments  ................................................................................................................ 61 
 Adverse Events  ................................................................................................................... 61  7.2.1
7.3 Patient related outcomes  .......................................................................................................  61 
 Dermatology Life Quality Index (DLQI) questionnaire  .............................................. 61  7.3.1
 EQ-5D-5L questionnaire  .................................................................................................... 61  7.3.2
 Work Productivity and Activity Impairment Questionnaire: General 7.3.3
Health Problem (WPAI:GH) modified for Rosacea.  .................................................... [ADDRESS_403548] satisfaction questionnaire ................................................................................ 62  7.3.4
7.4 Other assessments  ................................................................................................................. 62 
 Photography  ......................................................................................................................... 62  7.4.1
 Facial redness colorimetric measurements  ................................................................ 62  7.4.2
7.5 Appropriateness of measurements  ................................................................ .................... 63 
8. ADVERSE EVENT  ................................................................ .......................................................... 64  
8.1 Definiti ons .................................................................................................................................. 64 
 Adverse Events (AE)  .......................................................................................................... 64  8.1.1
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.113322  
version Final dated 10-FEB-2017 
Page 14 of 106 CONFIDENTIAL 
 Serious Adverse Events (SAE)  ........................................................................................ 64  8.1.2
 Unexpected adverse drug reaction  ................................................................................ 65  8.1.3
 Adverse event reporting period  ...................................................................................... 65  8.1.4
 Severity  .................................................................................................................................. 66  8.1.5
 Relationship to the study drug(s) and/or clinical trial procedure  .......................... [ADDRESS_403549] reaction  ................................................... 69  8.2.3
8.3 Procedures for reporting pregnancies  ............................................................................... 72 
9. STATISTICAL METHODS PLANNED  ........................................................................................ 74 
9.1 Statistical and analytical plans  ............................................................................................ 74 
 Variables to be statistically analysed  ............................................................................ 74  9.1.1
 Populations analysed, evaluability and limitations / evaluation of Bias  .............. 75  9.1.2
 Data presentation and graphics  ...................................................................................... 76  9.1.3
 Statistical analyses  ............................................................................................................ 76  9.1.4
9.2 Sample size determination  .................................................................................................... 77 
 Historical data and assumptions  .................................................................................... 77  9.2.1
 Sample size calculation  .................................................................................................... 77  9.2.2
10. TRAINING / MONITORING / DATA MANAGEMENT / QUALITY ASSURANCE  ............... 78 
10.1  Personnel training  ................................................................................................................... 78 
10.2  Clinical monitoring  .................................................................................................................. 78 
10.3  Data management  .................................................................................................................... 78 
10.4  Quality assurance / audit / inspection  ................................................................................ [ADDRESS_403550] CONSIDERATIONS  .................... 79 
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.[ADDRESS_403551] (IRB) or ethics committee (EC)  ........................................... [ADDRESS_403552] information sheet / informed consent  ................................................................. [ADDRESS_403553]  ......................................................................................................................... 82  
13. ATTACHMENTS  ............................................................................................................................. 84  
13.1  ATTACHMENT# 1  ..................................................................................................................... 84 
13.2  ATTACHMENT# 2  ..................................................................................................................... 88 
13.3 ATTACHMENT# 3  ..................................................................................................................... 92 
13.4 ATTACHMENT# 4  ..................................................................................................................... 94 
 
  
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.[ADDRESS_403554] OF ABBREVIATIONS AND DEFINITIONS OF TERMS 
Abbreviation  Term  
AE Adverse Event  
APT All Subjects Treated (Safety Population)  
CDMS  Clinical Data Management System  
CEA Clinician’s Erythema Assessment  
CMH  Cochran -Mantel -Haenszel  
CPM  Clinical Project Manager  
CRA  Clinical Research Associate  
CRF Case Report Form  
COPD   Chronic Obstructive Pulmonary Disease  
CRO  Contract Research Organization  
DLQI  Dermatology Life Quality Index  
DMP  Data Management Plan  
EC Ethics Committee  
EQ-5D EuroQol -[ADDRESS_403555] In (first subject who signs the Informed Consent Form)  
GCP  Good Clinical Practice  
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.[ADDRESS_403556]  
ICF Informed Consent Form  
ICH International Conference on Harmonization  
i.e. That is (Latin: id est)  
IGA Investigator ’s Global Assessment  
IND Investigational New Drug  
IPL  Intense Pulsed Light   
IRB Institutional Review Board  
ISF Investigator Site File  
ITT Intent -To-Treat  
IUD Intra Uterine Device  
IVM Ivermectin  
LOCF  Last Observation Carried Forward  
LSI Last Subject In (Last subject randomized /assigned to treatment)  
LSO Last Subject Out (Last subject who completed last clinical trial visit)  
MedDRA  Medical Dictionary for Regulatory Activities  
MR Modified Release  
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.[ADDRESS_403557]  
PRO  Patient Reported Outctome  
PP Per Protocol  
QD Once Daily (Latin: quaque die)  
SAE Serious Adverse Event  
SAP Statistical Analysis Plan  
SAS Statistical Analysis  System (SAS Institute Inc., Cary, NC)  
SD Standard Deviation  
SIN Subject Identification Number  
SOC  System Organ Class  
SOP  Standard Operating Procedure  
SPF Sun Protection Factor  
SmPC  Summary  of Product Characteristics  
TOC  Table of Contents  
UPT Urine Pregnancy Test  
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.113322  
version Final dated 10-FEB-2017 
Page 19 of 106 CONFIDENTIAL 
Abbreviation  Term  
UV Ultraviolet  
WPAI:GH  Work Productivity and Activity Impairment Questionnaire:  General Health  
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.113322  
version Final dated 10-FEB-2017 
Page 20 of 106 CONFIDENTIAL 
1. SYNOPSIS 
Clinical trial title:  
Efficacy comparison of Ivermectin  1% topi[INVESTIGATOR_326963] 40 mg Modified release (MR) capsules 
versus Ivermectin 1% topi[INVESTIGATOR_326967].  
 
Short title  (± acronym) : ANSWER study  - oraceA soolaNtra aSsociation  in patients With severE Rosacea  
 
Project number:  
838 Clinical trial phase:  
IV for US  
IIIb For Canada and Europe  Clinical trial period  
Planned  First Subject In: Q2 [ADDRESS_403558] Out:  Q1 2018  
 
   
Objective(s):  The main objective of this study is to evaluate the efficacy of Ivermectin 1% 
topi[INVESTIGATOR_326963] 40 mg Modified release (MR) capsules  
versus Ivermectin 1% topi[INVESTIGATOR_326968].  
 
The Safety and Patient Reported Outcomes (PRO) will be also evaluated.  
 
Methodology:  This is a multi -center, randomized, investigator -blind , controlled and 
parallel -group study in subjects with severe rosacea characterized by 
[CONTACT_327020] (papules and 
pustules).  
Total number of planned subjects:  A total of 270 subjects will be enrolled (i.e. 135  subjects in each group).  
Total number of planned sites:  Approximately 50 sites  
Approximate number of 
subjects/site:  Approximately [ADDRESS_403559]/site  
Country(ies) involved:  [LOCATION_003], Canada and Europe  (ie: [LOCATION_013], Czech Republic, Hungary, and 
Poland ). 
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.113322  
version Final dated 10-FEB-2017 
Page 21 of 106 CONFIDENTIAL 
Clinical trial title:  
Efficacy comparison of Ivermectin  1% topi[INVESTIGATOR_326963] 40 mg Modified release (MR) capsules 
versus Ivermectin 1% topi[INVESTIGATOR_326967].  
 
Short title  (± acronym) : ANSWER study  - oraceA soolaNtra aSsociation  in patients With severE Rosacea  
 
Project number:  
838 Clinical trial phase:  
IV for US  
IIIb For Canada and Europe  Clinical trial period  
Planned  First Subject In: Q2 [ADDRESS_403560] Out:  Q1 2018  
 
   
Population and main inclusion 
criteria:  Male or female subjects with severe rosacea, age of 18 years or older, with 
>20 to maximum 70 inflammatory lesions (papules and pustules) on the 
face & Investigator’s Global Assessment (IGA) score 4; meeting specific 
inclusion/exclusion criteria.  
Clinical trial duration per subject  12 weeks  
Number of visits:  Up to 5 visits  for subjects at Screening/Baseline, Week 4, Week 8, and 
Week 12.    
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.113322  
version Final dated 10-FEB-2017 
Page 22 of 106 CONFIDENTIAL 
Clinical trial title:  
Efficacy comparison of Ivermectin  1% topi[INVESTIGATOR_326963] 40 mg Modified release (MR) capsules 
versus Ivermectin 1% topi[INVESTIGATOR_326967].  
 
Short title  (± acronym) : ANSWER study  - oraceA soolaNtra aSsociation  in patients With severE Rosacea  
 
Project number:  
838 Clinical trial phase:  
IV for US  
IIIb For Canada and Europe  Clinical trial period  
Planned  First Subject In: Q2 [ADDRESS_403561] Out:  Q1 [ADDRESS_403562]:   
Ivermectin 1%  cream (Soolantra® 1% Cream  in the US, Soolantra® 10mg/g in 
Europe and Rosiver® 10mg/g in Canada ) associated with Doxycycline 40 mg 
MR (30 mg Immediate Release & 10 mg Delayed Release beads) capsules 
(Oracea® in the US, Oraycea® /Efracea® in  Europe and Apprilon®in Canada)  
 
 
Ivermectin 1%  cream: Topi[INVESTIGATOR_326969], approximately one small pea 
size amount per facial region (right and lef t cheeks, forehead, chin, and 
nose) once a day  
 
Doxycycline 40 mg MR (30 mg Immediate Release & 10 mg Delayed 
Release beads): 1 Capsule once -daily 
 
 
12 weeks  Name:  
 
 
 
 
[CONTACT_327079]:  
Dose/concentration:  
Total daily dose:  
Mode and frequency of administration:  
Location of treated area:  
 
 
Duration of treatment:  
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.113322  
version Final dated 10-FEB-2017 
Page 23 of 106 CONFIDENTIAL 
Clinical trial title:  
Efficacy comparison of Ivermectin  1% topi[INVESTIGATOR_326963] 40 mg Modified release (MR) capsules 
versus Ivermectin 1% topi[INVESTIGATOR_326967].  
 
Short title  (± acronym) : ANSWER study  - oraceA soolaNtra aSsociation  in patients With severE Rosacea  
 
Project number:  
838 Clinical trial phase:  
IV for US  
IIIb For Canada and Europe  Clinical trial period  
Planned  First Subject In: Q2 [ADDRESS_403563] Out:  Q1 [ADDRESS_403564]:  Ivermectin 1%  cream (Soolantra® 1% Cream  in the US, Soolantra® 10mg/g in 
Europe and Rosiver® 10mg/g in Canada ) associated with CD2475 -101 
(Oracea® ) oral placebo capsules . 
 
Ivermectin 1%  cream: Topi[INVESTIGATOR_326969], approximately one small pea 
size amount per facial region (right and left cheeks, forehead, chin, and 
nose) once a day  
 
 CD2475 -101  ( Oracea® )  placebo: 1 Capsule once -daily 
 
 
12 weeks  Name:  
 
[CONTACT_327079]:  
Strength/concentration:  
Total daily dose:  
Mode and frequency of administration:  
Location of treated area:  
 
Duration of treatment:  
Non-investigational product to be 
provided for the clinical trial:  Gentle Skin Cleanser  
Facial Moisturizer SPF 30  
Urine Pregnancy Kits  
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.113322  
version Final dated 10-FEB-2017 
Page 24 of 106 CONFIDENTIAL 
Clinical trial title:  
Efficacy comparison of Ivermectin  1% topi[INVESTIGATOR_326963] 40 mg Modified release (MR) capsules 
versus Ivermectin 1% topi[INVESTIGATOR_326967].  
 
Short title  (± acronym) : ANSWER study  - oraceA soolaNtra aSsociation  in patients With severE Rosacea  
 
Project number:  
838 Clinical trial phase:  
IV for US  
IIIb For Canada and Europe  Clinical trial period  
Planned  First Subject In: Q2 [ADDRESS_403565] Out:  Q1 2018  
 
   
Measurement criteria  Efficacy  
 Inflammatory lesion count by [CONTACT_327021]  
 Severity on the diffuse persistent  facial erythema of rosacea based on 
Clinician’s Erythema Assessment (CEA) evaluated by [CONTACT_327022]  
 Severity of rosacea based on Investigator’s Global Assessment (IGA) 
evaluated by [CONTACT_327021]  
 Severity of stinging/burning s ensation evaluated by [CONTACT_327023] 
 Global assessment of Ocular signs and symptoms, if present at 
baseline, evaluated by [CONTACT_327024]  
 Number  of flushing per week evaluated by [CONTACT_327025]  
 Severity of flushing evaluated by [CONTACT_327026]  
 Global improvement in rosacea evaluated by [CONTACT_327027]  
 Adverse Events (AEs) throughout the study  
 
Others  
 Dermatology Life Quality Index (DLQI) questionnaire at Baseline and 
the last visit  
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.113322  
version Final dated 10-FEB-2017 
Page 25 of 106 CONFIDENTIAL 
Clinical trial title:  
Efficacy comparison of Ivermectin  1% topi[INVESTIGATOR_326963] 40 mg Modified release (MR) capsules 
versus Ivermectin 1% topi[INVESTIGATOR_326967].  
 
Short title  (± acronym) : ANSWER study  - oraceA soolaNtra aSsociation  in patients With severE Rosacea  
 
Project number:  
838 Clinical trial phase:  
IV for US  
IIIb For Canada and Europe  Clinical trial period  
Planned  First Subject In: Q2 [ADDRESS_403566] Out:  Q1 2018  
 
   
Analys ed variables  Primary efficacy variable  
 Percent change from Baseline in Inflammatory Lesion count at Week 
12. 
 
Secondary efficacy variables  
 Percent change from Baseline in Inflammatory Lesion count at each 
intermediate visit  
 CEA at each post -Baseline visit: % of subjects across scores  
 IGA at each post -Baseline visit: % of subjects across scores  
 Stinging/burning at each post -Baseline visit: % of subjects across 
scores  
 Percen t change from Baseline (medical history) in terms of flushing 
count per week  
 Change from Baseline (medical history) in mean score severity per 
week  
 Global improvement in rosacea at the last visit: % of subjects across 
scores  
 
Exploratory efficacy variable s 
 Global assessment of Ocular signs and symptoms at each post -
Baseline visit: % of subjects across scores  
 
Safety variables  
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.113322  
version Final dated 10-FEB-2017 
Page 26 of 106 CONFIDENTIAL 
Clinical trial title:  
Efficacy comparison of Ivermectin  1% topi[INVESTIGATOR_326963] 40 mg Modified release (MR) capsules 
versus Ivermectin 1% topi[INVESTIGATOR_326967].  
 
Short title  (± acronym) : ANSWER study  - oraceA soolaNtra aSsociation  in patients With severE Rosacea  
 
Project number:  
838 Clinical trial phase:  
IV for US  
IIIb For Canada and Europe  Clinical trial period  
Planned  First Subject In: Q2 [ADDRESS_403567] Out:  Q1 2018  
 
   
Principal statistical methods and 
sample size calculation:  Centers considered too small may be combined to create  analys is-center. 
The Per Protocol (PP) population will consist of all enrolled and 
randomized subjects, except subjects who have major deviations from the 
protocol. The Intent -to-Treat (ITT) population will consist of the entire 
population enrolled and randomize d. The last observation carried forward 
(LOCF) method will be used to impute missing values of lesion counts. 
Analysis population definitions and pooling of centers will be decided 
before the database lock and unblinding.  
 
The primary objective of this trial is to demonstrate the superiority of 
Ivermectin  associated with Doxycycline MR vs. Ivermectin associated with 
Placebo, in terms of % change from Baseline in Inflammatory Lesion count 
at Week 12.  
 
The primary efficacy cr iterion will be analyzed by [CONTACT_327028] -
Mantel -Haenszel (CMH) statistic, stratified by [CONTACT_384] (or analysis -center) 
after ridit transformation with the row mean difference statistics, testing the 
hypothesis of equality. The p -value will have to be inf erior to 0.05 at Week 
12, on ITT/LOCF population.  PP analysis will be also performed to assess 
the robustness of the results obtained on ITT/LOCF population.  
 
The other variables will be analyzed similarly as primary analysis on 
appropriate population. Ea ch test will be two -sided, at the 0.[ADDRESS_403568] characteristics (previous medication, concomitant medication, 
demographics, baseline characteristics…), lesion counts and adverse 
events, will be summarized by [CONTACT_9086] (usual statistics and 
frequency distribution).  
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.113322  
version Final dated 10-FEB-2017 
Page 27 of 106 CONFIDENTIAL 
 
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.113322  
version Final dated 10-FEB-2017 
Page 28 of 106 CONFIDENTIAL 
2. BACKGROUND AND RATIONALE 
2.1 MEDICAL BACKGROUND AND RATIONALE FOR THE CLINICAL TRIAL  
Rosacea is a chronic inflammatory disease that affects around 10% of the population in 
Europe. Clinical characteristics include diagnostic features (persistent centrofacial erythema, 
phymatous changes); primary features (transient erythema or flushing, inflammatory 
papules/pustules, telangiectasia, ocular manifestations) and secondary features (burning 
sensation, stinging sensation, oedema, dry sensation) in various combinations1.1,1.2. Following 
the onset of the disease, patients with rosacea will experience cycles of relapse and 
remission of symptoms throughout their lives. Rosacea usually presents in the second or third 
decade of life, with prevalence of rosacea varying from less than 1% to more than 20%1.3,1.4. It 
is reported more frequently in fair -skinned people1.5,1.6,1.7.  Rosacea is known to have a 
negative impact on quality of life and is associated with depression and social isolation, 
hampering both social and professional lives. In a recent National Rosacea Society survey of 
1675 patients, 95% in patients with severe symptoms reported an adverse impact on their 
general outlook on life, highlighting that the emotional impact on patients appears to increase 
as symptoms become more severe1.8. 
 
Patients with inflammatory lesion of rosacea (papulo-pustular) show a chronic and recurrent 
course of their disease and it is usually accompanied by a persistent central facial erythema, 
potentially associated with telangiectasia. Eruptions usually occur on the center of the face 
with frequent involvement of the forehead and chin. The etiology of rosacea remains 
unknown, with both genetic and environmental factors potentially impacting pathogenesis. 
These etiological factors include enhanced vasomotor lability, immune system and 
sebaceous gland abnormalities, and greater susceptibility to heat and ultraviolet (UV) light 
exposure1.9. Patients with rosacea are reported to have an upregulated innate immune 
system, which can be triggered by [CONTACT_327029] (including certain foods, UV exposure and 
temperature changes). This heightened immune response induces signaling cascades 
associated with inﬂammatory and vasoregulatory  pathways. In addition, microorganisms such 
as the hair follicle mite Demodex folliculorum  have been suggested to play a key role. 
Penetration of the mite into the dermis may stimulate a delayed hypersensitivity reaction and 
inflammation. Several published studies report abnormally high numbers of Demodex  in 
subjects with papulo-pustular rosacea1.8.  
 
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.113322  
version Final dated 10-FEB-2017 
Page 29 of 106 CONFIDENTIAL 
In rosacea, the frequency of outbreaks varies with time, ranging from once or twice a year to 
continuous presence of symptoms. Management of the inflammatory lesions and the 
associated erythema warrants adherence with continued therapy1.10. Treatment options for 
rosacea with inflammatory lesions include various topi[INVESTIGATOR_326970], 
metronidazole, azelaic acid, and sodium sulfacetamide-sulfur1.11,1.12. Systemic treatment with 
sub- antimicrobial dose formulation of doxycycline (referred to as doxycycline 40 mg modified 
release)  incorporating 30-mg immediate-release and 10-mg delayed-release beads 
administered once daily; first FDA-approved (2006) as oral treatment for rosacea with 
papulopustular lesions. Doxycycline 40 mg modified-release (Oracea®) has shown to 
decrease both gene expression and protein levels of MMPs, KLK, and cathelicidin, which 
resulted in a reduction in inflammatory lesion counts . By [CONTACT_327030], doxycycline [ADDRESS_403569] in rosacea 
patients1.10. 
 
Ivermectin is a macrocyclic lactone derivative with dual anti-inflammatory and anti-parasitic 
properties. Approved for the treatment of onchocerciasis, strongyloidiasis and scabies in 
humans by [CONTACT_112621], and in lotion foam for topi[INVESTIGATOR_326971]. Oral ivermectin has 
been demonstrated to be effective as an anti-parasitic agent in reducing the number of 
Demodex mites in demodicidosis and in blepharitis. Ivermectin (IVM) has also been shown to 
exert anti-inflammatory effects by [CONTACT_327031]-induced production of 
inflammatory cytokines, including tumor necrosis factor- alpha (TNF- α) and interleukin (IL) -1β, 
while increasing the anti-inflammatory cytokine IL-10. Ivermectin is able to suppress 
production of the inflammatory mediators and modulation of NO, iNOS, COX-2, and PGE- 2 
release which are major contributing factors during the inflammatory process. It ’s therapeutic 
effect as a topi[INVESTIGATOR_326972], its anti-inflammatory and 
anti-demodex properties1.10. 
 
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.113322  
version Final dated 10-FEB-2017 
Page 30 of 106 CONFIDENTIAL 
The approval of Ivermectin 1% cream (FDA, 2015 ) for the treatment of the inflammatory 
lesions of rosacea was based upon two identically-designed large vehicle-controlled Phase 3 
randomized trials that demonstrated efficacy and safety in adults with moderate to severe 
papulopustular rosacea on a 12-week treatment period. In both studies, a greater proportion 
of subjects in the IVM 1% group achieved treatment success. Ivermectin was superior to 
vehicle in terms of reduction from baseline in inflammatory lesion counts (76% and 75% 
versus 50% for both vehicle groups, respectively)1.13. For Doxycycline the two placebo-
controlled pi[INVESTIGATOR_30338] 3 trials evaluated the efficacy and safety of doxycycline 40 mg 
modified release (MR) once daily versus placebo in participants with moderate to severe 
rosacea. These participants had [ADDRESS_403570] follow-up assessment at 3 weeks 
throughout the entire 16- week study compared with placebo (P≤ 0.005). Study by [CONTACT_327032].1.[ADDRESS_403571]-line treatment to target the 
inflammatory lesions of rosacea, which can be used in combination with systemic doxycycline 
modified-release as per the recent Canadian Rosacea guideline1.15 to provide an optimal 
treatment approach considering all inflammatory pathways involved in rosacea with 
inflammatory lesions. 
 
Unlike clinical studies evaluating monotherapy approaches, clinicians often use a combination 
of topi[INVESTIGATOR_326973], as an increased or additive 
benefit has been suggested with combination regimens. Topi[INVESTIGATOR_326974] 1% and 
oral anti-inflammatory doxycycline (40 mg MR, modified-release) are both approved for the 
treatment of rosacea with inflammatory papules and pustules. Associating those two 
products, each having demonstrated a good safety profile and efficacy on rosacea features, 
should lead to optimized clinical outcomes in a complex disease that has been proven difficult 
to manage comprehensively and would reflect a controlled study of that which is already 
prescribed in clinical practice1.15. In an attempt to further optimize comprehensive 
management of severe rosacea, this study aims to investigate the efficacy, patient 
satisfaction and safety of the association of topi[INVESTIGATOR_98709] 1% cream and oral Doxycycline 
MR 40mg once a day treatment. 
 
 
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.[ADDRESS_403572] PROFILE  
The products used in this clinical trial are Ivermectin 1% cream and Doxycycline MR [ADDRESS_403573] information ( PI-SmPC) for detailed efficacy and safety information. 
2.3 RISK/B ENEFIT ASSESSMENT  
Rosacea is a chronic , non-life-threatening skin disease characterized by [CONTACT_327033] a persistent central facial erythema and recurrent eruptions of inflammatory lesions 
(i.e., papules, pustules, or both).  
The two investigational products are marketed individually for rosacea treatment and with proven 
efficacy and good safety profile including severe rosacea population. 
Whatever the randomization arm, all study subjects will benefit from an efficient and safe 
rosacea treatment. 
The association of investigational products is not expected to raise new tolerability issues and 
has the potential to reach to better and possibly faster efficacy outcome. 
 
3. CLINICAL TRIAL OBJECTIVES AND CLINICAL HYPOTHESIS 
3.1 CLINICAL TRIALS OBJECTIVES 
The main objective of this study is to evaluate the efficacy of Ivermectin 1% topi[INVESTIGATOR_326975] 40 mg capsules MR compared with Ivermectin 1% topi[INVESTIGATOR_326976]. 
The Safety and Patient Reported Outcomes (PRO) will be also evaluated. 
3.2 CLINICAL HYPOTHESIS  
Associating IVM 1% cream and oral Doxycycline [ADDRESS_403574] only been evaluated individually so far, but never as an association.  
This study aims to assess both treatment evaluations on rosacea symptoms and will allow for 
the evaluation of the potential benefit of such treatment association on cumulative efficacy, time 
to onset of action with 2 products in rosacea, safety, and patient satisfaction needed in severe 
condition of rosacea. 
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.113322  
version Final dated 10-FEB-2017 
Page 32 of 106 CONFIDENTIAL 
 
 
4. SELECTION AND DISPOSITION OF CLINICAL TRIAL POPULATION 
4.1 NUMBER OF SUBJECTS  
A total of 270 subjects will be enrolled (i.e. 135 subjects in each group) at approximately 50 sites 
located in the [LOCATION_003], Canada and Europe ([LOCATION_013], Czech Republic, Hungary, and Poland).  
4.2 CLINICAL TRIAL POPULATION  
Subjects who meet all of the following criteria will be eligible for the clinical trial. Some criteria 
are to be checked at screening visit and/or at baseline visit, as specified by [CONTACT_193058]. 
 Inclusion criteria 4.2.[ADDRESS_403575] meet all of the following inclusion 
criteria:  
1. Male or female subject age ≥ 18 years or older;  
2. Subject with a minimum of 20 but not more than 70 inflammatory lesions (papules and 
pustules) of rosacea on the face at Baseline visit; 
3. Subject with severe rosacea with papulopustular lesions (according to the Investigator’s 
Global Assessment, IGA score rated 4);  
4. Female Subject of childbearing potential must have a negative urinary pregnancy test 
(UPT) at baseline visit (UPT should have a sensitivity of 25 IU/L or less). They must agree 
to use/continue a highly effective and approved contraceptive method(s) for the duration of 
the study and at least [ADDRESS_403576] study drug(s) use. A highly effective method of 
contraception being defined as: 
 bilateral tubal ligation; 
 combined   oral   contraceptives   (estrogens   and   progesterone)   or implanted or 
injectable contraceptives with a stable dose for at least 1 month prior to Baseli ne 
visit; 
 hormonal intra-uterine  device (IUD)  inserted at least 1 month prior to Baseline 
visit; 
 vasectomized partner for at least 3 months prior to Baseline 
OR  
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.[ADDRESS_403577]-menopausal (absence of menstrual 
bleeding for one year prior to clinical trial entry without any other medical reasons), 
hysterectomy or bilateral oophorectomy prior to clinical trial entry. 
6. Willing and able to comply with all of the time commitments and procedural requirements 
of the clinical trial protocol.  In particular, subject must adhere to the visit schedule, 
concomitant therapy prohibitions, and must be compliant with the treatment at study visits. 
7. Understand and sign an Informed Consent Form (ICF) and photo consent (when 
appropriate) at screening, prior to any investigational procedures being performed.  
8. Apprised of the Health Insurance Portability and Accountability Act (HIPAA), if in the US, or 
the Personal Information Protection and Electronic Documents Act (PI[INVESTIGATOR_15654]) if in Canada 
[or the equivalent in other regions] and is willing to share personal information and data, as 
verified by [CONTACT_2960] a written authorization at the screening/baseline. 
 
 Exclusion criteria 4.2.[ADDRESS_403578] with particular forms of rosacea (rosacea conglobata, rosacea fulminans, isolated 
pustulosis of the chin, isolated rhinophyma) or other facial dermatoses that may be 
confounded with papulopustular rosacea, such as perioral dermatitis, facial keratosis 
pi[INVESTIGATOR_22785], acute lupus erythematosus, actinic telangiectasia or seborrheic dermatitis and acne 
vulgaris 
2. Subject with more than 2 nodules of rosacea (a circumscribed, elevated, solid lesion more 
than 1.0cm in diameter with palpable depth) on the face 
3. Subject with known allergies or sensitivities to any components of the formulation of the 
study drugs being tested (either Ivermectin 1% cream or Doxycycline, see package 
inserts) 
4. Female who is lactating. 
5. Female who intends to conceive a child during the clinical trial during the study period and 
for at least [ADDRESS_403579] study drug(s) use. 
6. Currently participating in any other clinical trial of a drug or device OR participated within 
30 days prior to baseline OR is in an exclusion period (if verifiable) from a previous clinical 
trial. 
7. The subject has received, applied or taken the following treatments within the specified 
time frame prior to the Screening/Baseline visit: 
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.113322  
version Final dated 10-FEB-2017 
Page 34 of 106 CONFIDENTIAL 
 
 
 
 
 
 
 
 
Topi[INVESTIGATOR_326977]:  
Astringents or abrasives (scrubs, exfoliating cleansers and products containing 
salicylic acid or alcohol)  2 days  
Antibiotics (e.g. metronidazole or macrolides)  4 weeks  
Benzoyl Peroxide  4 weeks  
Anti-rosacea drugs (e.g. azelaic  acid, brimonidine, oxymetazoline)  4 weeks  
Immunomodulators  4 weeks  
Corticosteroids  4 weeks  
Retinoids  4 weeks  
Any procedure on the face (e.g. laser, intense pulsed light -IPL, facial peel, 
dermabrasion, electrocoagulation, Thermage®) 6 weeks  
Systemic treatments : 
Antibiotics (e.g. cyclines, macrolides, metronidazole)  4 weeks  
Corticosteroids  4 weeks  
Immunomodulators  4 weeks  
Oral Ivermectin  4 weeks  
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.113322  
version Final dated 10-FEB-2017 
Page 35 of 106 CONFIDENTIAL 
Other drugs used for the treatment of acne or rosacea (eg: spi[INVESTIGATOR_8407])  4 weeks  
Oral retinoids  12 weeks  
Anticoagulants of the dicoumarol type  4 weeks  
Sulphonylurea oral antidiabetic agents  1 week  
Other treatments:  
Inhaled Corticosteroids (for asthma or chronic obstructive pulmonary disease -
COPD)  4 weeks  
Oxymetazoline  (any route; e.g. eye drops, nasal sprays…) or vasodilators  [ADDRESS_403580] is unwilling to refrain from use of prohibited medication during the clinical trial 
(see section 4.3.5 ) 
9. Subject who is vulnerable as defined in Section 1.61 of the International Conference on 
Harmonisation (ICH) Guideline for Good Clinical Practice (GCP); eg: adult subject under 
guardianship, hospi[INVESTIGATOR_326978] a public or private institution for a reason other than 
the research, and subject deprived of his/her freedom 
10. The subject has history of alcohol or drug abuse (positive urine drug screen and/or alcohol 
test) within the previous [ADDRESS_403581] is a study site staff member (investigator, study nurse, etc.) or a relative of 
one. 
12. The initiation of a hormonal method of contraception within [ADDRESS_403582] with clinically significant abnormal laboratory finding at the screening/baseline visit 
or an underlying known disease, a surgical or medical condition, which in the judgment of 
the Investigator, would put the subjects at risk (e.g., uncontrolled chronic or serious 
diseases which would normally prevent  participation in any clinical study, such as cancer, 
leukemia or hematologic dyscrasia), or might confound the study assessments (e.g. other 
dermatological diseases), or might interfere with the subject’s study participation (e.g. 
planned hospi[INVESTIGATOR_16366]) 
14. Subject who is at risk in terms of precautions, warnings, and contra-indication (see 
package insert) 
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.[ADDRESS_403583] exposed to excessive UV radiation within two weeks prior to the Baseline visit, or 
subjects planning exposure during the study (e.g. phototherapy, occupational exposure to 
the sun, planned holidays with excessive sun during the study period, tanning salon) 
 
4.3 PRIOR AND CONCOMITANT THERAPI[INVESTIGATOR_326979] 4.3.1
Previous therapi[INVESTIGATOR_014] (drugs and/or procedures) are defined as therapi[INVESTIGATOR_326980] [ADDRESS_403584] application/intake.  
An exception will be made on the last rosacea treatment taken, where no limit on period of time 
will be applied upon  data collection. 
 
Concomitant therapi[INVESTIGATOR_83778]: 
 any existing therapi[INVESTIGATOR_326981]/baseline visit , or 
 any changes to existing therapi[INVESTIGATOR_014] (such as changes in dose or formulation) during the 
course of the clinical trial, or 
 any new therapi[INVESTIGATOR_326982]/baseline visit 
 Categories 4.3.2
The following two categories will be considered for previous and concomitant therapi[INVESTIGATOR_014]:  
 Drugs/therapi[INVESTIGATOR_44793], but not limited to, prescription, over-the-counter (OTC), birth 
control pi[INVESTIGATOR_3353]/patches/hormonal devices, vitamins, moisturizers, sunscreens, herbal 
medicines/supplements, and homeopathic preparations. 
 Medical and surgical procedures including, but not limited to, laser/radiation procedures, 
dermal fillers, X-rays, etc. 
 
 Recording 4.3.3
Previous and concomitant therapi[INVESTIGATOR_326983]/Therapi[INVESTIGATOR_326984] (for 
drugs/therapi[INVESTIGATOR_014]) and/or on the Medical and Surgical Procedures form (for medical/surgical 
procedures) in the case report form (CRF). 
Concomitant therapi[INVESTIGATOR_79005], reviewed, and updated at each trial visit. 
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.113322  
version Final dated 10-FEB-2017 
Page 37 of 106 CONFIDENTIAL 
Any new concomitant therapy or modification of an existing therapy may be linked to an adverse 
event (AE). A corresponding Adverse Event Form must be completed to account for the change 
in therapy, except in some cases such as therapy used for prophylaxis, dose modification for a 
chronic condition, etc. 
 Authorised therapi[INVESTIGATOR_326966]. 4.3.4
Unless listed in the exclusion criteria above or in the prohibited therapi[INVESTIGATOR_014] (see sections 4.2.2  and 
4.3.5 ), all therapi[INVESTIGATOR_162870]. 
Subjects must use the study-provided cleanser, moisturizer/sunscreen for skin care as described 
in section 6.2. 
Subjects may use cosmetics and make-up if they are applied after study drug application. 
Subjects may not use foundation make-up or study provided moisturizer/sunscreen on the days 
of the visits. 
 Prohibited therapi[INVESTIGATOR_326966]  4.3.5
The following therapi[INVESTIGATOR_326985]/or safety 
assessment of the investigational products, or because they may interact with the metabolism of 
the investigational products: 
 All topi[INVESTIGATOR_326986] (section 4.2.2 ) 
 Chronic use (>14 days) of  sulpha drugs, erythromycin, cephalosporin, and quinolones 
 Use of systemic tetracycline antibiotics or tetracycline-like (doxycycline) antibiotics in 
conjunction with penicillin (drug interactions with bacteriostatic and bactericidal effects). 
 Use of Rifampi[INVESTIGATOR_2513], barbiturates, carbamazepi[INVESTIGATOR_050], diphenylhydantoin, primidone, phenytoin 
(hepatic enzyme inducers wh ich will thereby [CONTACT_327034]’s half -life) and 
cyclosporine. 
 The concurrent use of tetracycline and methoxyflurane has been reported to result in fatal 
renal toxicity   
 For ocular rosacea if new therapy required like topi[INVESTIGATOR_326987] (including 
antibiotics eye drops or steroids); but can continue if stable over the past 2 weeks and 
planned to be maintained during the study (authorised to use lubricating ointments, artificial 
tears, eyelid care during the study). 
 Chronic use (>14 consecutive days) of NSAIDs, except chronic use of aspi[INVESTIGATOR_326988]-
analgesic dose (≤ 325mg QD) is permitted for patients requiring platelet aggregation inhibitors 
(dose modifications on PI [INVESTIGATOR_9106], refer SmPC) 
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.113322  
version Final dated 10-FEB-2017 
Page 38 of 106 CONFIDENTIAL 
 Use of protein pump inhibitors 
 Any other drugs/proc edures which at the investigator’s judgement are liable to interfere or 
interact with the efficacy and the safety of investigational products. 
Antacids and vitamins containing aluminum, calcium, or magnesium are allowed only if are taken 
at least 1.[ADDRESS_403585], GALDERMA R&D will be notified to discuss possible alternatives prior to administration 
of a prohibited therapy and to discuss the pertinence and the modalities for the subject to 
continue in the clinical trial. 
4.4 PROCEDURES / REASONS FOR DISCONTINUATION  
An Investigator may decide to discontinue a subject from the clinical trial for safety reasons. 
Although the importance of completing the entire clinical trial should be explained to the subject 
by [CONTACT_327035], any subject is free to discontinue his/her participation in this clinical 
trial at any time and for whatever reason, specified or unspecified, and without prejudice.  
Subjects who discontinue the clinical trial prematurely should be fully evaluated, whenever 
possible.  
The procedures designated for th e early termination visit will be completed for all premature 
discontinuation subjects. The appropriate eCRF pages for the next scheduled visit should be 
completed. 
For all subjects who prematurely discontinue the clinical trial, the reason must be carefully 
documented by [CONTACT_327036], and, if applicable, on the Adverse Event Form 
for discontinuation due to an AE.  
A subject who has been randomized and assigned a kit number cannot be replaced by [CONTACT_327037]/she discontinues the clinical trial for any reason. 
In the case of early termination, the investigator should ensure that the subject receives 
appropriate therapy for his/her condition. 
GALDERMA R&D may also decide to prematurely terminate or suspend the clinical trial or the 
participation of a subject in the clinical trial. 
All data gathered on the subject prior to termination will be made available to GALDERMA R&D . 
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.113322  
version Final dated 10-FEB-2017 
Page 39 of 106 CONFIDENTIAL 
Reasons for clinical trial completion/discontinuation, as listed on the Exit Form of the CRF are 
described below:  
Normal Study  Completion  Subject completes the clinical trial as planned in protocol.  
Pregnancy  Withdraw the subject from the clinical trial following the procedure described in th e 
protocol section 8.[ADDRESS_403586] relocation, schedule conflicts, etc… Does not 
include AE. . Explain the reason for withdrawal in the comments section of the CRF 
Exit Form.  
Protocol Violation  Explain the violation in the comments section of the CRF Ex it Form  
Lost to Follow -up Confirm with 2 documented phone calls and a certified letter (delivery receipt 
requested) without response. Explain in the comments section of the CRF Exit Form.  
Other  This category is to be used for a subject who discontinues for a reason other than 
those specified in the predefined categories above. Explain the reason for 
discontinuation in the comments section of CRF Exit Form.  
If reason for discontinuation is “subject request”  or “other ”, the subject must be questioned to 
rule out the possibility of an AE; this should be documented in the CRF. 
  
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.113322  
version Final dated 10-FEB-2017 
Page 40 of 106 CONFIDENTIAL 
5. INVESTIGATIONAL PLAN 
5.1 OVERALL CLINICAL TRIAL DESIGN  
This clinical trial will be conducted as a  multi-center, randomized, investigator-blind, controlled 
and parallel-group study in subjects with severe rosacea characterized by [CONTACT_327038] (papules and pustules), and meeting other specific 
eligibility criteria. 
A total of 270 subjects will be enrolled (ie: 135 in each group) in approximately 50 sites in the 
[LOCATION_003], Canada and Europe. Approximately 5 subjects are planned from each site. 
Subjects will be enrolled at baseline and treated for 12 weeks with either Ivermectin 1% cream 
associated with Doxycycline 40 mg MR (CD2475-101)  capsules or Ivermectin 1% cream 
associated with CD2475- 101 placebo capsules. 
There will be two parallel groups, randomized in a ratio of [1:1].  
There will be up to 5 trial visits: at baseline, Screening/Baseline, Week 4 (±3 days), Week 8 (±3 
days), and Week 12 (±5 days). 
5.2 DISCUSSION OF CLINICAL TRIAL DESIGN  
IVM 1% cream and oral Doxycycline [ADDRESS_403587] been individually approved for rosacea 
treatment in US, Canada and Europe, with demonstrated efficacy and good safety profile 
including in severe rosacea population. 
They will be used in this trial in their indication and approved dose and regimen. 
Unlike clinical studies evaluating monotherapy approaches, clinicians often use a combination of 
topi[INVESTIGATOR_326973], as an increased or additive benefit has 
been suggested with combination regimens.  
Topi[INVESTIGATOR_98729] (10 mg/g) and systemic, oral Doxycycline 40 mg MR (modified-
release) have only been evaluated individually so far, but never as an association. The 
combined therapeutic approach of both drugs association may be more beneficial, but has never 
been assessed for rosacea treatment in a randomized clinical trial.  
To ensure an appropriate evaluation of this association benefit, it will be compared to Ivermectin 
1% topi[INVESTIGATOR_326989] 40 mg MR (CD2475- 101).   
This clinical trial will compare the efficacy and safety of Ivermectin 1% topi[INVESTIGATOR_326990] 40 mg Modified release (MR) capsules compared to Ivermectin 1% topi[INVESTIGATOR_326991]. 
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.[ADDRESS_403588] In (FSI) to Last Subject Out 
(LSO)] is approximately [ADDRESS_403589] who participates in the clinical trial. 
The planned duration of recruitment (i.e. From FSI to Last Subject In (LSI)) is approximately 6 
months. 
The clinical trial may be terminated by [CONTACT_327039]/her clinical trial site at any time with 
appropriate notification to GALDERMA R&D . Likewise, GALDERMA R&D may terminate the 
clinical trial and/or the participation of the clinical trial site(s) with appropriate notification.  
The expected duration of subject participation is 12 weeks. 
  
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.113322  
version Final dated 10-FEB-2017 
Page 42 of 106 CONFIDENTIAL 
5.4 CLINICAL TRIAL FLOW CHART  
PROCEDURES  STUDY VISITS  
Visit 1  Visit 2  Visit 3  Visit 4  
Screening/
Baseline  Week 4  
(±3 d)  Week 8  
(±3 d)  Week 12  
 (±5 d)  
Informed Consent/Photography Consent  X    
Inclusion/Exclusion Criteria  X    
Demographics/Medical History (including 
flushing  and co -morbidities ) / Previous 
Therapi[INVESTIGATOR_014]  (including rosacea last treatment)  X    
Concomitant Therapi[INVESTIGATOR_014]  X X X X 
Urine Pregnancy Test (UPT)a X   X 
Inflammatory (Papules and Pustules) 
Lesion Counts  X X X X 
Clinician Erythema Assessment (CEA)  X X X X 
Investigator’s Global Assessment (IGA)  X X X X 
Severity of Stinging/Burning sensation  X X X X 
Global assessment of Ocular signs and 
symptoms  X X X X 
Flushing  via diary (frequency and 
severity)  X X X X 
Subject’s Global Improvement in 
Rosacea     Xd 
Standardized Facial photography  / facial 
redness colorimetric measurements b   X X X X 
Adverse Event (AE)c X X X X 
DLQI Questionnaire  X   Xd 
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.113322  
version Final dated 10-FEB-2017 
Page 43 of 106 CONFIDENTIAL 
EQ-5D-5L Questionnaire  X   Xd 
WPAI:  GH questionnaire  X   Xd 
Subject Satisfaction Questionnaire     Xd 
Dispensation of Investigational Products, 
Subject Diary and Other Supplies  X X X  
Return of Investigational Products and 
Subject Diary   X X X 
Exit form     Xd 
a. For subjects of childbearing potential only. UPT is mandatory at Screening/Baseline and at last visit ( Week 12 or before if early 
termination ). 
b. Photography consent and standardized photography  + facial redness colorimetric measurements  at selected centers only.  
c. AEs are to be collected starting from the signing of the Informed Consent Form.  
d. Assessments to be performed in case of early termination visit. 
 
 
 
 
5.5 CLINICAL TRIAL VISIT DESCRIPTION AND PROCEDURES  
 Visit 1 – Screening/Baseline visit 5.5.[ADDRESS_403590] read, understand, date and sign an approved informed consent form 
(ICF). Give a dated and signed copy to each subject and parent/guardian if applicable.  
3. If subject female of childbearing potential agrees to participate to the clinical trial, make 
sure she is using the requir ed method(s) of contraception (see inclusion criteria 4.2.1 ). 
Make sure that the urine pregnancy test is done and the result is negative before subject 
inclusion in the trial 
4. Log into the electronic case report form (eCRF) to get a Subject Identification Number. 
5. Question the subject about demography, medical history (including flushing and rosacea 
co-morbidities), prior and concomitant therapi[INVESTIGATOR_014] (including rosacea last treatment). 
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.[ADDRESS_403591] ’s baseline evaluation must be 
conducted after the washout period has been completed. 
7. Check inclusion/exclusion criteria (see sections 4.2.1  and 4.2.2 ). 
8. Conduct facial inflammatory lesion count (see section 7.1.1 ). 
9. Assess and record the severity of the diffused facial erythema of rosacea using CEA (see 
section 7.1.2 ). 
10. Perform and record Investigator’s Global Assessment (IGA) (see  section 7.1.3 ). 
11. Evaluate and record the severity of subject’s facial stinging/burning sensation (see  section 
7.1.4 ). 
12. Assess and record the severity of the  Ocular signs and symptoms (see section 7.1.5 ). 
13. Record in medical history the frequenc y of flushing (average per week) and the severity as 
reported by [CONTACT_327040] (see section 7.1.6). 
14. Ask subject to complete the Dermatology Life Quality Index (DLQI) questionnaire (see 
13.1) and review for completion; 
15. Ask subject to complete the EQ-5D-5L questionnaire (see 13.2) and review for completion; 
16. Ask subject to complete the WPAI: GH questionnaire (see 13.3) and review for completion; 
 
17. For selected sites only, take photographs of the face according to the provided 
photographic procedure, only if subject has agreed on the approved ICF. 
18. For selected sites only, perform facial redness colorimetric measurements. 
19. Record the occurrence of any new adverse events and/or any changes to adverse events. 
20. If subject is eligible according to the inclusion/exclusion criteria, the smallest subject kit 
number available must be assigned to the subject by [CONTACT_093]; 
21. Fill in a prescription form , dispense the subject card, including the SIN, kit number and ask 
the subject to go see the person in charge of study medication , as relevant (hereafter 
referred to as investigational product dispenser ). 
22. The person in charge of investigational product dispensation described here  as the 
investigational product dispenser will: 
a) Dispense to the subject the baseline investigational products from the subject kit 
according to the prescription form. 
b) Affix the tear-off portion of the label on the product dispensation log and report the 
required information on the labels if applicable. 
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.113322  
version Final dated 10-FEB-2017 
Page 45 of 106 CONFIDENTIAL 
c) Dispense to the subject associated non-investigational produc ts  
d) Dispense the Subject diary. 
e) Provide appropriate verbal and written instructions on how to properly use the 
investigational products and how to keep a record of missed doses. The first dose of 
topi[INVESTIGATOR_326992]/taken by [CONTACT_327041]. 
f) Emphasize the importance of complying with the given instructions and treatments; 
instruct the subject to bring back the dispensed investigational product(s) together 
with the subject diary at the next visit. 
23. For all female subjects, emphasize the guidelines about contraception and risks in case of 
pregnancy  
24. Schedule the next three visits [Week 4 (± 3 days), Week 8 (± 3 days) and Week 12 (± 5 
days)]. 
 Visit 2 and 3 – Week [ADDRESS_403592] the occurrence of any new adverse events and/or any 
changes to adverse events that were ongoing at the previous clinical trial visit. Document 
all changes in the CRF. 
2. Enquire whether any concomitant therapi[INVESTIGATOR_326993], stopped, or changed since 
the subject ’s last visit. Document all changes in the CRF. 
3. Conduct facial inflammatory lesion count (see section 7.1.1 ). 
4. Assess and record the severity of the diffused facial erythema of rosacea using CEA (see 
section 7.1.2 ). 
5. Perform and record Investigator’s Global Assessment (IGA) (see section 7.1.3 ). 
6. Evaluate and record the severity of subject’s facial stinging/burning  sensation (see section 
7.1.4 ). 
7. Assess and record the severity of the Ocular signs and symptoms (see section 7.1.5 ). 
8. Check subject’s diary and r ecord the frequency and severity of flushing for each week as 
reported by [CONTACT_327042] (see section 7.1.6 ). 
9. Take photographs of the face according to provided photographic procedure (for selected 
sites only).  
10. For selected sites only, perform facial redness colorimetric measurements. 
11. Fill in a prescription form and ask the subject to go see the Investigational product 
dispenser, as relevant. 
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.[ADDRESS_403593] dispenser will: 
a) Check the investigational products; review the subject’s diary for completion and 
accuracy interview the subject about compliance. All missing tubes must be 
documented on the eCRF comments section and on other accountability forms. 
b) Record the investigational products and Facial Moisturizer compliance on the eCRF. 
c) Dispense to the subject the investigational products from the subject kit according to 
the prescription form. 
d) Affix the tear-off portion of the label on the product dispensation log and report the 
required information on the labels if applicable. 
e) Dispense to the subject associated non-investigational products (if necessary) and give back 
the subject diary. 
f) Provide appropriate verbal and written instructions on how to properly use the 
investigational products and how to keep a record of missed dose(s).  
g) Emphasize the importance of complying with the given instructions and treatments; 
instruct the subject to bring back the dispensed investigational product(s) together 
with the subject diary at the next visit. 
13. Check and confirm for next follow-up visit schedule until Final visit 4 - Week 12 (± 5 days). 
In case of early termination of the Clinical Trial for whatever reason: 
a) The subject will be fully evaluated 
b) The procedures designated for the last clinical trial visit should be performed 
 
 Visit 4- Week 12 / Last clinical trial visit  5.5.[ADDRESS_403594] the occurrence of any new adverse events and/or any 
changes to adverse events that were ongoing at the previous clinical trial visit. Document 
all changes in the CRF. 
2. Enquire whether any concomitant therapi[INVESTIGATOR_326993], stopped, or changed since 
the subject ’s last visit. Document all changes in the CRF. 
3. Conduct facial inflammatory lesion count (see section 7.1.1 ). 
4. Assess and record the severity of the diffused facial erythema of rosacea using CEA (see 
section 7.1.2 ). 
5. Perform and record Investigator’s Global Assessment (IGA) (see section 7.1.3 ). 
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.[ADDRESS_403595]’s facial stinging/burning sensation (see section 
7.1.4 ). 
7. Assess and record the severity of the Ocular signs and symptoms (see section 7.1.5 ). 
8. Check subject’s diary and record the frequency of flushing for each week as reported by 
[CONTACT_327042] (see section 7.1.6 ). 
9. Ask the subject to assess her/his Global Improvement in Rosacea (see section 7.1.7 ) and 
record the outcome; 
10. Ask subject to complete the Dermatology Life Quality Index (DLQI) questionnaire (see 
13.1) and review for completion; 
11. Ask subject to complete the EQ-5D-5L questionnaire (see 13.2) and review for completion; 
12. Ask subject to complete the WPAI: GH questionnaire (see 13.3) and review for completion; 
13. Ask subject to complete the Subject Satisfaction questionnaire (see 13.4) and review for 
completion; 
14. Perform a urine pregnancy test (UPT) for female subjects of childbearing potential. 
15. For selected sites only, take photographs of the face according to the provided 
photographic procedure, only if subject has agreed on the approved ICF. 
16. For selected sites only, perform facial redness colorimetric measurements. 
17. Complete the Exit form in the CRF and give the reason for clinical trial discontinuation. 
18.  Investigational product dispenser will: 
a) Check the investigational products; review the subject’s diary for completion and 
accuracy interview the subject about compliance. All missing tubes must be 
documented on the eCRF comments section and on other accountability forms. 
b) Record the investigational products and Facial Moisturizer compliance on the eCRF. 
  
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.[ADDRESS_403596]  
Trade Name  [CONTACT_327080]® cream  Oracea®  capsules  Not applicable 
Name [CONTACT_327081]  
(CD5024)  Doxycycline 
monohydrate (CD2475 -
101) CD2475 -101 placebo 
capsule  
Form  Cream  Capsule  Capsule  
Dose or 
Concentration  1% 
 40 mg MR (30 mg 
Immediate Release & 10 mg 
Delayed  
Release beads)  
 Not applicable  
Manufacturer  
(Name [CONTACT_3816])  Galderma Production Inc, 
Montreal (Canada)  
  Catalent  Pharma 
Solutions, LLC 
Winchester, Kentucky 
[ZIP_CODE] [LOCATION_003]  Catalent Pharma 
Solutions, LLC 
Winchester, Kentucky 
[ZIP_CODE] [LOCATION_003]  
Packaging (primary)  30g CRC tube  Bottle of 30 capsules  Bottle of 30 capsules  
Storage 
Requirements*  Store at 20 to 25°C (68°F 
to 77°F), excursions 
permitted between 15°C 
and 30°C (for US supplies)  
 Store at room 
temperature between 
59°F to 86°F (15°C to 
30°C)  Store at room 
temperature between 
59°F to 86°F (15°C to 
30°C)  
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.113322  
version Final dated 10-FEB-2017 
Page 49 of 106 CONFIDENTIAL 
*the most restrictive storage conditions on the labels will be applied. 
 
 
 
 
 
 
 
 
 Method of treatment assignment  6.1.[ADDRESS_403597] will be generated by [CONTACT_154500] R&D 
and transmitted to the assigned clinical packaging organization for labeling. The RANUNI routine 
of the SAS systems will be used for the kit number generation.  
A subject kit will be composed of: 
either Ivermectin 1% cream and Doxycycline 40 mg MR (CD2475-101) capsules , or Ivermectin 
1% cream and CD2475- [ADDRESS_403598] kit. 
Treatments will be balanced in 1:[ADDRESS_403599] will be secured in a locked cabinet and in an electronic file with restricted 
access to only the designated personnel directly responsible for labeling and handling the 
clinical trial treatments until the clinical trial database is locked and ready to be unblinded. 
At the baseline visit, all eligible and enrolled subjects will be dispensed treatment (ie: tube of 
Ivermectin and bottle of Doxycycline [ADDRESS_403600] kit, which will 
be allocated in chronological order of inclusion into the clinical trial, without omitting or skippi[INVESTIGATOR_326994].  
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.[ADDRESS_403601] Identification Number (SIN) 6.1.[ADDRESS_403602] meeting all inclusion/exclusion criteria will be 
allocated a unique subject identification number automatically generated by [CONTACT_51084] .  
During the whole clinical trial, the subject will only be identified using the SIN for all 
documentation and discussion. 
 Instructions for use and administration 6.1.[ADDRESS_403603] how to use/take the 
investigational products or how to perform the investigational product application at the baseline 
visit.  
Ivermectin 1% cream should be applied once daily in the evening. Subjects will be instructed to 
apply one small pea size of cream on the forehead, chin, nose, and each cheek (ie a total of 5 
pea-sized amounts). The product should be evened out to a thin film on the entire face. 
Application to the following areas must be avoided: eyes, eyelids, inner nose, mouth, and lips. 
Should this occur, areas will have to be washed with plenty of water. 
Subjects will be instructed to wash hands immediately after product application. 
Doxycycline [ADDRESS_403604] one hour prior to or two hours after meals. 
The treatment administration is further described below. 
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.[ADDRESS_403605]  
oral placebo  
Concentration  1% 40 mg MR  
(30 mg Immediate Release & 
10 mg Delayed  
Release beads)  NA 
Dose regimen  Once daily in the evening  Once daily in the morning  Once daily in the morning  
Period of administration  12 weeks  12 weeks  12 weeks  
Route of administration  Cutaneous to the entire 
face Oral Oral 
 
6.2 OTHER SUPPLIES  
 Gentle Skin Cleanser :  
Cetaphil Redness Relieving® Foaming Face Wash (or equivalent) 
 
 Facial Moisturizer SPF 30:  
Cetaphil redness relieving® facial moisturizer1 (or equivalent) 
 
 Urine Pregnancy Tests (UPT) :  
Arrow ™ (or equivalent)  
 
All the above supplies will be provided by [CONTACT_1034].  
 
 
Gentle Skin Cleanser: 
Subjects should use the Gentle Skin Cleanser to wash the face prior to applying the study 
treatment. 
                                                      
1 SPF= 30  (per ISO [ZIP_CODE]:2010 SPF norm)  / SPF= 20 (per FDA Fed Register 2011:76 SPF norm)   
 
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.113322  
version Final dated 10-FEB-2017 
Page 52 of 106 CONFIDENTIAL 
No specific labels will be used. 
 
Facial Moisturizer SPF 30: 
Subjects will be recommended to use the provided moisturizer/sunscreen during the study, 
within 1 hour after study drug application, especially for outdoor activities and/or sun exposure.  
Subjects will be instructed not to apply the provided moisturizer/sunscreen on the days of study 
visits until the study assessments are performed. 
No specific labels will be used. 
 
6.[ADDRESS_403606] ’s kit including visit boxes with an 
affixed and a tear-off portion.  
For treatment documentation, the affixed portion of the label will remain on the appropriate 
packaging. The tear-off portion of the label will be removed at the time of dispensation and 
attached to the corresponding product dispensation log. 
If more than one batch is used with different expi[INVESTIGATOR_1659], in order to maintain blinding, only 
one expi[INVESTIGATOR_5695], the most conservative, will be listed on the container label. 
The same kit number will be printed on each investigational product container and subject kit 
labels. 
The Subject Identification Number and subject ’s initials will be manually entered onto the subject 
kit/visit box and the dispensation date will be manually entered onto the visit label box. 
The labels (including tear-off part) will also contain information required by [CONTACT_327043] (GMP), Good Clinical Practice (GCP) and local regulations and will be printed in local 
languages. 
 
 
 
 
 
6.[ADDRESS_403607] MANAGEMENT  
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.[ADDRESS_403608] 
a complete inventory of all investigational products and assume responsibility for their storage, 
accountability and dispensation. 
The Investigator or designee will sign the original “Receipt of Clinical Supplies ” Form (or any 
acknowledgment of receipt) upon receipt and inspection of the supplies, send the signed copy 
and the temperature curve to GALDERMA R&D  and retain the receipt in the Investigator Site 
File (ISF). 
All supplies sent to the investigator site will be accounted for and in no case used in any 
unauthorized situation.  
At the end of the trial, all used and unused investigational products will be returned to 
GALDERMA R&D or the designated contractor for further reconciliation, appropriate inventory 
and destruction. 
 Dispensing 6.4.[ADDRESS_403609] kit will contain 3 visit treatment boxes (each for 1 month of treatment) to be 
dispensed at Baseline, Week 4 and Week 8 visits, respectively.  
Each visit treatment box will contain 1 tube of Ivermectin 1% cream and 2 bottles of Doxycycline 
40 mg MR or its placebo.  
 
All efforts will be taken to keep the evaluator (investigator or designee) blinded by [CONTACT_327044]/her contact [CONTACT_327045]. 
The investigational product dispenser must be different from the clinical trial efficacy and safety 
evaluator in order to maintain the blind (see section 6.4).Treatment kits will be dispensed in 
ascending sequential order according to the chronological order of enrolment of subjects into the 
clinical trial. 
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.[ADDRESS_403610] dispenser about the importance of 
being compliant with clinical trial treatment(s) throughout the clinical trial as well as the 
importance of returning their investigational product (used and/or not used) at each follow- up 
visit. 
The investigational product(s) will be collected and counted at all visits by [CONTACT_327046]. 
Subjects will also be questioned regarding the application technique, intake, frequency and 
missed doses of investigational products and the use of any other additional topi[INVESTIGATOR_2855], systemic 
drug as well as OTC product. 
A subject ’s diary will be given to each subject in order to record the use of investigational 
products and Facial Moisturizer. The investigational product dispenser will review the subject ’s 
diary at every visit. 
The return of investigational products will be appropriately documented on the product 
dispensation log by [CONTACT_327047]. 
During the data review meeting, investigational product compliance for all subjects will be 
determined and reviewed by [CONTACT_456] ’s clinical team for possible exclusion from the Per 
Protocol (PP) population. 
 Storage of investigational product 6.4.4
The investigator has to agree to keep all investigational products in a safe, temperature 
controlled and secure area with restricted access, in accordance with applicable regulatory 
requirements (e.g., in the site pharmacy, if applicable). 
Investigational products should be stored at appropriate storage conditions specified by 
[CONTACT_154500] R&D (see section 6.1.1 ). 
 Return of investigational product 6.4.[ADDRESS_403611] about the importance of returning 
their investigational products (used and/or not used) at each trial visit. 
In the event of early termination/suspension of the clinical trial for safety reasons, a rapid recall 
of the trial products will be initiated.  The investigator or designee must immediately instruct all 
subjects to stop the clinical trial treatment regimen and return the investigational products to the 
clinical trial site. 
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.113322  
version Final dated 10-FEB-2017 
Page 55 of 106 CONFIDENTIAL 
As a general procedure, GALDERMA R&D  will provide the investigator with a detailed list of 
units being recalled so that any of the units remaining on site can be put immediately into 
quarantine. 
6.5 BLINDING  
 Verification of blinding 6.5.1
The clinical trial design is considered investigator-blind based on the following rationale: 
1. Oral placebo capsules will be free from marking unlike the Oracea capsules. Aside from 
this difference, both oral trial products will be filled in the same type of primary packaging 
materials (ie: bottle) and there will be no other sign that could indicate which one is the active 
product and which one is the placebo.  
2. The investigational products will be dispensed by [CONTACT_327048] 
(investigator or designee) designated as the investigational product dispenser in order to 
maintain the blind. 
3. Additionally, both the investigational product dispenser and the subject will be instructed 
not to discuss the investigational products with the evaluator (investigator or designee) 
4. The investigational product dispenser and the investigator will not have access to the 
unblinded randomization list. 
The randomization list will be maintained secured in a locked cabinet and/or an electronic file 
with restricted access to only the designated personnel directly responsible for labeling and 
handling the study drugs at the Sponsor’s/designee’s location. The independent statistician 
providing analyses requested will be able to access the randomization list upon request. 
 Unblinding during the clinical trial 6.5.2
Emergency un-blinding during the clinical trial may be required for therapeutic or for regulatory 
reasons (e.g. for expedited safety reporting). 
A blind-break system will be available for Investigators.  At the clinical trial center, the blinded 
label containing the identification of the assigned study drug(s) will be revealed in emergency 
situations only.  In such an emergency, the Investigator will only break the blind for the subject 
involved. 
Treatment identification for emergency purposes will be possible with “unblinding envelopes”, 
stating the treatment number, investigational product identification, batch number and 
investigational product expi[INVESTIGATOR_320], as applicable.   
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.[ADDRESS_403612] notify the sponsor immediately in the event of such an emergency (see 
contact [CONTACT_77268] 8.2.2 ).  If possible, the investigator should notify the sponsor before 
breaking the blind in order to discuss this decision with the sponsor.  The investigator is required 
to document each case of emergency un-blinding on the appropriate form (provided by [CONTACT_429]) and send the completed form to the sponsor immediately.  
 
7. EFFICACY AND SAFETY ASSESSMENT 
Clinical evaluations should be performed by [CONTACT_22960] (investigator or designee) 
throughout the clinical trial.  
If it is not possible to use the same evaluator to follow a subject, then evaluations should overlap 
for at least one visit in order to examine the subject together and discuss findings. This should 
be documented in medical source documents. 
 
7.1 EFFICACY ASSESSMENTS  
 Inflammatory Lesion Count  7.1.1
The evaluator will perform inflammatory lesion count on facial papules and pustules of rosacea 
at baseline and then at each visit.  
Inflammatory lesions are defined as follows: 
 Papule – A small, solid elevation less than one centimeter in diameter 
 Pustule – A small, circumscribed elevation of the skin, which contains yellow white 
exudates. 
Papules and pustules will be counted separately on each of the five facial regions (forehead, 
chin, nose, right cheek and left cheek). Nodules  (defined as a circumscribed, elevated, solid 
lesion more than 1.0 cm in diameter with palpable depth) will not be included in the count of 
inflammatory lesions , and subjects are not eligible if they have more than 2 nodules on the 
face at screening/baseline visit.  
 
 Clinician’s Erythema Assessment (CEA)  7.1.[ADDRESS_403613]’s diffuse persistent facial erythema of rosacea by 
[CONTACT_746] a static (“snap shot”) evaluation of erythema severity, at a socia l distance of 
approximately [ADDRESS_403614]’s erythema of rosacea and CEA must be 
evaluated after the inflammatory lesion count. 
 
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.[ADDRESS_403615] clear; slight redness  
2 Mild erythema; definite redness  
3 Moderate erythema; marked redness  
4 Severe erythema; fiery redness  
 
 
 Investigator’s Global Assessment (IGA) 7.1.[ADDRESS_403616]’s rosacea at each visit by [CONTACT_746] a static (“snap -shot”) 
evaluation, at a social distance of approximately [ADDRESS_403617] an IGA of 4 (severe) to be 
eligible for the study.  
 
Grade  Score  Clinical Description  
Clear  [ADDRESS_403618] Clear  1 Very few small papules/pustules, very mild erythema present  
Mild 2 Few small papules/pustules, mild erythema,  
Moderate  3 Several small or large papules/pustules, moderate erythema,  
Severe  4 Numerous small and/or large papules/pustules, severe erythema,  
 
 Stinging/Burning sensation  7.1.[ADDRESS_403619]’s facial stinging/burning sensation (a prickling 
pain sensation) during the last 24h at each visit.  
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.113322  
version Final dated 10-FEB-2017 
Page 58 of 106 CONFIDENTIAL 
 
Grade  Score  Clinical Description  
None  0 No stinging/burning  
Mild 1 Slight warm, tingling/stinging sensation; not really bothersome  
Moderate  2 Definite warm, tingling/stinging sensation that is somewhat 
bothersome  
Severe  3 Hot, tingling/stinging sensation that has caused definite discomfort  
 
 Ocular Signs and Symptoms 7.1.[ADDRESS_403620].  The 
Evaluator may identify ocular manifestations by [CONTACT_327049], redness of bulbar and/or 
palpebral conjunctivae, telangiectasia of conjunctiva and lid margin, lid or periocular erythema, 
or styes, and by [CONTACT_327050]- body  sensation, gritty feeling, burning, 
stinging, itching, dryness, light sensitivity, blurred vision, or decreased visual acuity.  
Grading of ophthalmological abnormalities in ocular rosacea will be based on clinical opi[INVESTIGATOR_326995]. 
 
Grade   Score  Clinical Description  
None  0 No ocular sign/symptom  
Mild [ADDRESS_403621] in medical history the frequency (number) of flushing as 
reported by [CONTACT_327051], moderate or severe. 
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.[ADDRESS_403622]’s diary where subject will be asked to report each day the flushing  epi[INVESTIGATOR_1841]. Investigator 
or designee will have to check with subject for diary completeness at each visit and report 
flushing information in the eCRF.  
  
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.[ADDRESS_403623]’s Global Improvement in Rosacea  7.1.[ADDRESS_403624] will evaluate his/her improvement in rosacea at last visit, compared with his/her 
rosacea condition before the study.   
 
[ADDRESS_403625] resolved  
(100% improvement from Baseline ) 
1 Excellent Improvement  Nearly all signs and symptoms cleared  
(90% improvement from Baseline ). Only minimal 
residual signs and symptoms remain  
[ADDRESS_403626] resolved  
(about 75% improvement from Baseline ) 
3 Good Improvement  Significant improvement, but many signs and 
symptoms remain (about 50% improvement from 
Baseline ) 
4 Minimal improvement  Slight overall improvement, but not clinically 
significant( about 25% improvement from Baseline ) 
5 No Change  Overall severity similar  from Baseline  
6 Worse  Worse  than Baseline  
 
  
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.113322  
version Final dated 10-FEB-2017 
Page 61 of 106 CONFIDENTIAL 
 
7.2 SAFETY ASSESSMENTS  
A safety assessment will be conducted for all subjects at the screening/baseline visit (from the 
Informed consent signature) and every subsequent visit. The safety parameters and AEs are to 
be recorded as specified in section 7.2.1 . 
 Adverse Events 7.2.1
Adverse events (AEs) are to be monitored throughout the course of the clinical trial.  All AEs 
occurring after the subject signs the informed consent should be recorded on the AE form on the 
eCRF. 
All AEs are to be reported on an Adverse Event Form of the eCRF with complete information as 
required. If AEs occur, the main concern will be the safety of the subject. At the time of the ICF 
signature, each subject must be provided with the name [CONTACT_327082]. 
All clinical medical events, whether observed by [CONTACT_327052]. Assessment of 
seriousness, severity and causality will be based on specific definitions. If the subject 
discontinues due to an AE, both the AE Form and the Exit Form should be completed. 
Subjects reporting a worsening of rosacea (worsening of any signs and symptoms of rosacea 
including but not limited to inflammatory lesions, persistent erythema and flushing) will be 
evaluated in detail. This includes the onset, duration and outcomes of those events, as well as a 
complete history and potential triggers of the concerned signs and symptoms of rosacea. 
 
7.3 PATIENT RELATED OUTCOMES 
 Dermatology Life Quality Index (DLQI) questionnaire 7.3.[ADDRESS_403627] visit, subjects will answer the 10-item DLQI questionnaire (see section 
13.1), a validated quality- of-life questionnaire specific to dermatological conditions. The 
investigator or delegate will then check all questions of the questionnaire for completeness prior 
to the subject leaving the study visit.  
 EQ-5D-5L questionnaire 7.3.[ADDRESS_403628] visit. 
EQ-5D-5L is a 5-level, 5-dimensional format standardized instrument for use as a measure of 
health outcome. Applicable to a wide range of health conditions and treatments, it provides a 
simple descriptive profile and a single index value for health status. EQ-5D was originally 
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.113322  
version Final dated 10-FEB-2017 
Page 62 of 106 CONFIDENTIAL 
designed to complement other instruments but is now increasingly used as a 'stand-alone' 
measure. EQ-5D-5L is designed for self-completion by [CONTACT_170496]. It is cognitively simple; 
taking only a few minutes to complete (see section 13.2). The investigator or delegate will then 
check all questions of the questionnaire for completeness prior to the subject leaving the study 
visit. 
 
 Work Productivity and Activity Impairment Questionnaire: General Health 7.3.3
Problem (WPAI:GH) modified for Rosacea. 
Subjects will answer the quality of life questionnaire WPAI: G H at Baseline visit and at last visit. 
The WPAI: G H questionnaire consists of six questions (see section 13.3). It is an instrument to 
measure impairments in both paid work and unpaid work. It measures absenteeism, 
presenteeism as well as the impairments in unpaid activity because of health problem during the 
past seven days. It has been validated to quantify work impairments for numerous diseases 
including dermatological diseases such as psoriasis1.16. In addition, the WPAI: G H questionnaire 
has been used to compare work impairments between treatment groups in clinical studies or 
between subjects with different disease severity levels. As per WPAI questionnaire adaptation 
guidelines, the questionnaire has been adapted for rosacea by [CONTACT_327053] ‘your health 
problems’ by ‘your rosacea’.  
The investigator or delegate will then check all questions of the questionnaire for completeness 
prior to the subject leaving the study visit. 
 Subject satisfaction questionnaire 7.3.[ADDRESS_403629] visit, subjects will complete a questionnaire (see section 13.4). 
 
 
7.4 OTHER ASSESSMENTS  
 Photography 7.4.1
Standardized photographs on the face (1 front view and 2 profile views) will be taken at selected 
investigational sites at each study visit. Pi[INVESTIGATOR_326996]. 
   Facial redness colorimetric measurements 7.4.2
Complementary facial redness colorimetric measurements will be performed using a 
Chromameter at selected investigational sites, depending on material availability. 
 
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.113322  
version Final dated 10-FEB-2017 
Page 63 of 106 CONFIDENTIAL 
 
7.5 APPROPRIATENESS OF MEASUREMENTS  
The clinical efficacy assessments will be based on inflammatory lesion counts, evaluation of 
facial erythema, stinging/burning sensation and flushing. The methods are established in the 
evaluation of rosacea products and used in previous studies with the study products. 
Safety is documented by [CONTACT_327054] a well-established 
process in clinical trials. In case of reporting of a worsening of rosacea, specific complementary 
data will be collected. 
Impact of study treatments on subjects’ quality of life will be measu red by [CONTACT_327055]. DLQI and EQ-5D-5L are two validated questionnaires for evaluating quality- of-
life: While EQ- 5D-3L is more general and not disease-specific, the DLQI focuses on the impact 
of dermatological diseases on the quality- of-life.  
The WPAI: GH questionnaire is a validated instrument to quantify work impairments for 
numerous diseases including dermatological conditions.  
To collect specifically the patient satisfaction outcome, a subject satisfaction questionnaire will 
be used at the end of the study to collect the subjects’ feedback on the treatment regimen, the 
level of satisfaction and future usage. 
  
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.113322  
version Final dated 10-FEB-2017 
Page 64 of 106 CONFIDENTIAL 
 
8. ADVERSE EVENT 
8.1 DEFINITIONS  
 Adverse Events (AE) 8.1.[ADDRESS_403630] a causal relationship with this treatment.  An AE can therefore be any unfavorable and 
unintended sign (including an abnormal laboratory value), symptom, or disease temporally 
associated with the use of a medicinal (investigational) product, whether or not related to the 
medicinal (investigational) product. 
Thus any new sign, symptom or disease, or clinically significant increase in the intensity of an 
existing sign, symptom or disease since the first visit (including the disease being treated), 
should be considered as an adverse event. Lack of efficacy should not be considered as an AE. 
Each new epi[INVESTIGATOR_44715] a chronic disease (e.g., hay fever, allergy, etc.) from the screening visit 
should be reported as a new AE. 
Notes: 
 Any new sign or symptom reported by [CONTACT_327056]. 
 There should be an attempt to report a diagnosis rather than the signs, symptoms or 
abnormal laboratory values associated with the report of an AE.  However, a diagnosis should 
be reported only if, in the Investigator ’s judgment, it is relatively certain.  Otherwise, 
symptoms, signs, or laboratory values should be used to describe the AE. 
 Pregnancy should not be considered as an adverse event but must be followed up as 
described in section 8.3 
 For an AE of irritation, the “date of onset ” should be the date that the first symptom occurred. 
 Serious Adverse Events (SAE) 8.1.2
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.[ADDRESS_403631] medical occurrence that at any dose:  
 results in death, 
 is life-threatening, 
 requires hospi[INVESTIGATOR_1081], 
 results in persistent or significant disability/incapacity, or 
 is a congenital anomaly/birth defect. 
Important medical events that may not result in death, be life-threatening, or require 
hospi[INVESTIGATOR_12475], based upon appropriate medical judgment, 
they may jeopardize the safety of the subject, and may require medical or surgical intervention to 
prevent one of the outcomes listed in this definition. Examples of such events are intensive 
treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasia, or 
convulsions that do not result in hospi[INVESTIGATOR_059]. 
Note: 
 The term “life-threatening ” refers to an event in which the subject was at risk of death at the 
time of the event; it does not refer to an event which hypothetically might have caused death 
if it was more severe. 
 Inpatient hospi[INVESTIGATOR_326997]. The criterion for the prolongation of hospi[INVESTIGATOR_326998]. Hospi[INVESTIGATOR_326999], (even if 
related to an AE), elective hospi[INVESTIGATOR_327000], admission to a day-care facility, social admission 
(e.g., if the subject has no place to sleep), or administrative admission (e.g., for a yearly 
examination). 
 Unexpected adverse drug reaction 8.1.[ADDRESS_403632] ’s participation. 
The sponsor should be informed if the investigator becomes aware of any unusual safety 
information or any safety information that appears to be drug-related involving a subject who has 
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.[ADDRESS_403633] appropriate according  his medical 
judgment. 
Mild Awareness of sign or symptom, but easily tolerated  
Moderate  Discomfort, enough to cause interference with usual activity  
Severe  Incapacitating with inability to work or perform usual activity  
 Relationship to the study drug(s) and/or clinical trial 8.1.6
procedure 
The investigator is to determine whether there is a reasonable causal relationship between the 
occurrence of the AE and exposure to the study drug(s) and/or clinical trial procedure. Medical 
judgment should be used to determine the relationship, considering all relevant factors, including 
pattern of reaction, temporal relationship, positive de-challenge or re-challenge, relevant medical 
history, and confounding factors such as co-medication or concurrent diseases. 
The expression “reasonable causal relationship ” is meant to convey in general that there are 
facts or arguments to suggest a causal relationship (International Conference on Harmonization 
(ICH) E2A, section IIIA 1). 
The relationship assessment for an AE is to be completed using the following definitions as a 
guideline for all adverse events occurring during clinical trials conducted or sponsored by 
[CONTACT_154500]: 
Reasonable possibility: 
According to the reporting investigator, there is a reasonable possibility (i.e. suggestive evidence 
or arguments) that there is a causal relationship irrespective of the dose administered between: 
 The study drug  (investigational product, active comparator, or vehicle, etc.) and the AE,  
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.113322  
version Final dated 10-FEB-2017 
Page 67 of 106 CONFIDENTIAL 
 The clinical trial protocol procedure (e.g., UV-induction, biopsy, xylocaine injection, blood 
test or intraocular pressure measurement, ancillary products provided by [CONTACT_456], 
such as moisturizers, etc. and the AE. 
The Investigator has to complete these 2 causality assessments on the AE form. 
No Reasonable Possibility: 
No suggestive evidence or arguments can be identified regarding a causal relationship between 
the investigational product or the clinical trial protocol procedure and the AE. 
 
 
 
8.[ADDRESS_403634]-baseline visit, the investigator (or sub-investigator) will enquire about adverse 
events using an open question taking care not to influence the subject ’s answer (e.g., “Have you 
noticed any change in your health since the last visit? ”). Direct questioning and examination wil l 
then be performed as appropriate. 
Any AE occurring during the AE reporting period, whether it is related to the study drug  or not, 
will be recorded immediately in the source document, and described in the Adverse Event Form 
with the date of onset, severity, relationship to the study drug ), and outcome, without omitting 
any requested and known information.  Additional information will be requested under certain 
circumstances. Adverse Events (AEs) assessed as related to the treatment will be monitore d 
until they are completely or satisfactorily resolved. Other AEs will be monitored until the last visit 
if they are not resolved or satisfactorily resolved. 
Adverse events assessed as related to the treatment or study procedure will be monitored until 
they have resolved or reached a stable condition. Other AEs will be monitored until the last visit 
if they have not resolved or reached a stable condition. The investigator will obtain and maintain 
in the subject ’s files all pertinent medical records, information and medical judgment from 
colleagues who assisted in the treatment and follow-up of the subject. If necessary, the 
investigator will contact [CONTACT_423] ’s personal physician or hospi[INVESTIGATOR_99391]. 
For SAEs (see section 8.2.2 ) and pregnancies (see section 8.3), the Sponsor is to be informed 
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.113322  
version Final dated 10-FEB-2017 
Page 68 of 106 CONFIDENTIAL 
immediately by e-mail/fax.  The event must be reported by [CONTACT_327057] e-mail to the Sponsor 
within 24 hours of receipt of the information (contact [CONTACT_8972] i n section 8 .2.2 ). 
 
 Procedure for reporting a serious adverse event 8.2.[ADDRESS_403635] do the following: 
1. Take prompt and appropriate medical action, if necessary. The safety of subject is 
the first priority. 
2. Ensure that the event is classified as an SAE. Immediately (no later than 24 hours) 
inform the Sponsor  of the event by [CONTACT_6968]/ fax/, and discuss further actions  to be 
taken: 
 
 GALDERMA R&D  
Name   
[CONTACT_327083]. during office hours   
Tel. outside office hours   
Fax   
Email  [EMAIL_6387]  
3. Print and complete the Serious Adverse Event form (available in the eCRF system as PDF 
document). Fax or send by [CONTACT_327058], accompanied any other relevant 
information or anonymized medical records (e.g., laboratory test results) within 24 hours of 

GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.113322  
version Final dated 10-FEB-2017 
Page 69 of 106 CONFIDENTIAL 
receipt of this information to the sponsor (see contact [CONTACT_73322]). The demographics, 
medical history, drugs/therapi[INVESTIGATOR_327001], and adverse event pages of the eCRF must be 
completed and available for review in the eCRF system at the time of the report. 
4. Monitor and record the progress of the event until it resolves or reaches a clinically 
stable outcome, with or without sequelae. For all additional follow-up evaluations, fax or 
send by e-mail all additional follow-up information on the SAE to the sponsor (see contact 
[CONTACT_73322]) within 24 hours of receipt of the updated information.  SAEs will be 
monitored until the Investigator and Sponsor agree that the event is satisfactorily resolved. 
5. Obtain and maintain in his/her files all pertinent medical records, information, and medical 
judgments from colleagues who assisted in the treatment and follow-up of the subject.  If 
necessary, contact [CONTACT_423] ’s personal physician or hospi[INVESTIGATOR_298422] 
6. Inform the sponsor of the final outcome of the event . Send a revised or updated SAE 
form and AE form, if appropriate. 
7. Prompt notification of SAEs by [CONTACT_327059]. GALDERMA 
has a legal responsibility to notify both the local regulatory authority and other regulatory 
agencies about the safety of a product under clinical investigation. GALDERMA will comply 
with country specific regulatory requirements relating to safety reporting to regulatory 
authorities, IRBs/IECs and investigators. Investigator safety reports are prepared for 
Suspected Unexpected Serious Adverse Reactions (S[LOCATION_003]Rs) according to local 
regulatory requirements and GALDERMA policy and are forwarded to investigators as 
necessary. An investigator who receives an investigator safety report describing an SAE(s) 
or other specific safety information (e.g., summary or listing of SAEs) from GALDERMA 
will notify the IRB/IEC, if appropriate according to local requirements. 
8. Comply with the applicable regulatory requirements related to the reporting of SAEs to 
your IRB/EC. 
 
 Procedure for suspected allergic contact [CONTACT_327060] 8.2.3
This is a general procedure and further details can be discussed with the sponsor. 
 Stop the trial product 
 Take a pi[INVESTIGATOR_327002]-affected surrounding skin  
 Document the event and report it immediately to the sponsor by [CONTACT_6968]/fax, within 24 hours of 
receipt of the information as described in section 8.2.2. 
 
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.[ADDRESS_403636] 
chamber on the skin of the upper back on either the right or left side of the center line (or 
the inner forearm if the back cannot be tested). If no test chamber is available on-site, 
patch test units will be provided. It may be preferable to perform the test under semi-
occlusive conditions depending on the irritant potential of the trial product and the intensity 
of the reaction that was observed. The method to be used will be discussed with the 
sponsor.  
5. Choose a skin site that was not previously involved in the inflammatory skin reaction. 
6. Cover it for [ADDRESS_403637] system dry 
8. After 48 hours, remove the tests and evaluate the site: 
- At approximately [ADDRESS_403638] removal (1st  reading) and, 
- 24 to 48 hours later (i.e. 72 or 96 hours after application) (2nd  reading). 
- A facultative 3rd  reading may be performed 96 to 120 hours later (i.e. 6 to 7 days after 
application of the patch) if the overall assessment so far equivocal or if asked by [CONTACT_103]. 
- Pi[INVESTIGATOR_327003]. 
 
Duration of trial 
product application  1st  Reading  2nd   Reading  3rd  reading  
(optional)  
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.[ADDRESS_403639] application ([ADDRESS_403640] removal)   [ADDRESS_403641] application ([ADDRESS_403642] 
removal)  [ADDRESS_403643] application (96 to 
120 hours after patch 
removal)  
 
9. Refer to the scoring system ( Spi[INVESTIGATOR_327004], R. [ZIP_CODE].17) used by [CONTACT_327061] (ICDRG) to assign a score at each reading:  
 
Score  Morphology  Interpretation  
- No skin changes in the tested area  Negative  
? Faint, non -palpable erythema  Doubtful reaction  
+ Palpable erythema (moderate edema or infiltrate), 
papules not present or scarce, vesicles not present  Weak positive reaction  
++ Strong infiltrate, numerous papules, vesicles present  Strong positive reaction  
+++ Erythema, infiltration, confluent vesicles, bullae or 
ulceration  Extreme positive reaction  
ir Inflammation sharply limited to the exposed area, lack 
of infiltrate, small petechiae, pustules, and efflorescence 
other than papules and vesicles  Irritant reaction  
Nt  Not tested  
 
10. At last reading, the investigator will provide an assessment regarding a possible 
sensitization reaction using the following scale: 
Sensitization Reaction  
0 Negative (absence of reaction or might be irritant reaction)  
1 Equivocal  
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.[ADDRESS_403644] will be initiated as directed by [CONTACT_456] (with 
individual ingredients at different concentrations if applicable, and possibly negative and 
positive controls) after a minimum of additional two weeks (but not later than 6 months) 
and after all signs and symptoms have resolved. The patch tests will be placed on the 
subject’s back (or the inner forearm if the back cannot be tested) distant from the site of 
the re-challenge test (e.g., the left upper back skin if the re-challenge test was done on the 
right side). Follow the same procedure for the patch test as for the re-challenge.  
14. In case of suspi[INVESTIGATOR_327005] (such as urticaria) 
A case by [CONTACT_327062]. 
 
8.[ADDRESS_403645](s), must be followed-up until outcome in order to ensure the complete 
collection of safety data on GALDERMA  product. 
If a subject becomes pregnant, the Investigator is to do the following: 
1. Withdraw the subject from the clinical trial   
2. Complete all appropriate visit evaluations and CRF pages. 
3. Immediately (no later than 24 hours) contact [CONTACT_327063]. 
4. Complete, as fully as possible, the pregnancy surveillance form – Part I:  History and 
start of pregnancy - provided by [CONTACT_327064], as fully as 
possible. Fax or send by [CONTACT_327065] 
24 hours of receipt of the information to the Sponsor. 
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.113322  
version Final dated 10-FEB-2017 
Page 73 of 106 CONFIDENTIAL 
 GALDERMA R&D  
Name   
[CONTACT_327083]. during office hours   
Tel. outside office hours   
Fax   
Email  [EMAIL_6387]  
 
5. Monitor and record the progress of the pregnancy until its outcome.  Contact [CONTACT_423] ’s 
regular physician (general practitioner or gynecologist) or hospi[INVESTIGATOR_327006]-up information. 
6. Inform the Sponsor of the progress by [CONTACT_248879]-monthly updates up  to the final outcome of 
the pregnancy. For all the additional follow-up evaluations, fax or send by e-mail the 
additional follow-up information to the sponsor within [ADDRESS_403646] can no longer be reached (lost to follow-up), documentation of the 
non-response/contact [CONTACT_298473] a letter (certified with return receipt) is 
required. 
At outcome of pregnancy, complete as fully as possible the pregnancy surveillance 
form – Part II:  Course and outcome of pregnancy, as full as possible. Inform the Sponsor 
by [CONTACT_6968]/ fax, then fax or send by e-mail this pregnancy form to the Sponsor within 
24 hours of receipt of the information. 
7. If the pregnancy leads to an abortion (voluntary abortion, spontaneous abortion or 
therapeutic abortion), in utero  death or congenital anomaly, follow the procedure for 
declaration of an SAE (see Section 8.2.2 ). 
  

GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.113322  
version Final dated 10-FEB-2017 
Page 74 of 106 CONFIDENTIAL 
9. STATISTICAL METHODS PLANNED 
9.1 STATISTICAL AND ANALYTICAL PLANS  
A Statistical Analysis Plan (SAP) will be developed as a separate document. The SAP will 
contain a more detailed and technical description of specific data conventions, calculations and 
of statistical procedures for executing the analyses that are specified in the sections of the 
clinical trial protocol below.  The SAP will be finalized prior to database lock and unblinding . 
Any change made to the finalized SAP will be documented in the clinical trial report. 
The purpose of the trial is to evaluate the efficacy of Ivermectin 1% topi[INVESTIGATOR_326990] 40 mg Modified release (MR) capsules versus Ivermectin 1% topi[INVESTIGATOR_327007]. 
The Safety and Patient Reported Outcomes (PRO) will be also evaluated. 
 Variables to be statistically analysed 9.1.1
The following variables will be analysed: 
 Primary efficacy variable  [IP_ADDRESS]
The primary endpoint is  the percent change from Baseline in Inflammatory Lesion count at Week 
12. 
 Secondary efficacy variables  [IP_ADDRESS]
The secondary efficacy endpoints are:  
 Percent change from Baseline in Inflammatory Lesion count at each intermediate visit 
 CEA at each post-Baseline visit: % of subjects across scores  
 IGA at each post-Baseline visit: % of subjects across scores 
 Stinging/burning at each post-Baseline visit: % of subjects across scores 
 Percent change from Baseline (medical history) in terms of flushing count per week over 12 
weeks 
 Change from Baseline (medical history) in terms of flushing severity score per week over 12 
weeks 
 Global improvement in rosacea at the last visit: % of subjects across scores 
 Exploratory efficacy variable  [IP_ADDRESS]
One exploratory endpoint is planned to be analyzed:  
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.[ADDRESS_403647]-Baseline visit: % of subjects 
across scores 
 Safety variables  [IP_ADDRESS]
 Incidence of adverse events 
 Incidence of serious adverse events 
 Patient Reported Outcomes (PRO)  [IP_ADDRESS]
 DLQI questionnaire at Baseline and the last visit  
 EQ-5D-5L questionnaire at Baseline and last visit  
 WPAI:GH questionnaire at Baseline and last visit  
 Subject Satisfaction Questionnaire at last visit  
 
    Populations analysed, evaluability and limitations / evaluation of Bias 9.1.[ADDRESS_403648] populations: 
 The Per Protocol efficacy population (PP)  [IP_ADDRESS]
This population will consist of all enrolled and randomised subjects, except subjects who have 
major deviations from the protocol. Major deviations will be defined during a data review meeting 
after data entry and before unblinding the clinical trial treatment. Major protocol deviations will be 
considered as having a possible effect on the interpretation of primary efficacy results and may 
include: inclusion criteria not respected, non-available efficacy assessment, interfering therapy at 
inclusion, etc. The primary efficacy endpoint will be analysed based on this population. 
 The Intent- to-Treat efficacy population (ITT) [IP_ADDRESS]
This population will consist of the entire population enrolled and randomised (i.e. assigned a kit 
number). The ITT population will be used for all variables except the safety variables. 
 The Safety population (All subject treated [APT])  [IP_ADDRESS]
This population will consist of the Intent- to-Treat population, after exclusion of subjects who 
never used the treatment with certainty based on monitoring report. The APT population will be 
only used for the safety variables (AEs). 
 Missing values  [IP_ADDRESS]
The last observation carried forward (LOCF) method will be used to impute missing values of 
Inflammatory Lesion count, CEA, IGA and Stinging/burning sensation. If no post-baseline data 
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.[ADDRESS_403649]. Thus, the number of subjects will not vary at each 
visit. The other missing values will not be replaced (observed data). 
 
 Data presentation and graphics 9.1.3
All continuous data will be summarized using usual statistics: number of values, mean, median, 
standard deviation, minimum and maximum, and by [CONTACT_267303] (n, %) for qualitative 
data. For ordinal data, both frequency distribution and usual statistics will be presented. All 
tables will be presented by [CONTACT_327066] (when applicable).  
Therapi[INVESTIGATOR_327008]. 
Those reported at screening or starting between screening and baseline visits and still 
continuing after baseline will be classified as concomitant therapi[INVESTIGATOR_014]. 
The adverse events will be descriptively summarized (n, %) for the safety population (APT). The 
adverse events will be descriptively summarized (n, %) by [CONTACT_327067] (SOC) and preferred term (MedDRA). Subjects will be descriptively 
summarized (n, %) by [CONTACT_2236] ( i.e. mild, moderate and severe) of adverse events, SOC and 
preferred terms. Deaths and serious adverse events will be reported as well as withdrawals due 
to adverse events. A subject will be counted only once per System Organ Class (SOC) and only 
once per preferred term even if more than one occurrence of an event was reported within a 
SOC or preferred term. In the summary by [CONTACT_327068], the adverse event with the 
highest intensity will be used. The subject will be counted only once per SOC (highest intensity 
whatever the AE within the SOC) and once per preferred term (highest intensity whatever the AE 
within the preferred term).  
 Statistical analyses 9.1.4
Any changes of the statistical analyses decided after the database lock will be justified and 
documented. 
 The definition of the populations will be finalized after a blind data review meeting, during which 
the distribution of subjects per site will be reviewed. In case of too small sites or in case of 
severe unbalance between the size of sites, some sites may be combined, e.g. per geographical 
area, to form analysis-center for purpose of stratification of the statistical analyses. 
The primary objective of this study will be to demonstrate the superiority of the Ivermectin 1% 
topi[INVESTIGATOR_326963] 40 mg MR capsules compared to versus Ivermectin 
1% topi[INVESTIGATOR_327009], in terms of Inflammatory Lesion count at week 12 .  
The primary efficacy endpoint will be analyzed by [CONTACT_327028]-Mantel-Haenszel (CMH, 
FREQ procedure from SAS®) statistic, stratified by [CONTACT_384] (or analysis-center) after ridit 
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.113322  
version Final dated 10-FEB-2017 
Page 77 of 106 CONFIDENTIAL 
transformation with the row mean difference statistics, testing the hypothesis of equality on 
ITT/LOCF population. PP analysis will also be performed to assess the robustness of the results 
obtained on ITT/LOCF population. The p-values will have to be inferior to 0.[ADDRESS_403650] characteristics (disposition, previous and concomitant therapi[INVESTIGATOR_014], study treatments 
duration/ compliance, demographics, baseline characteristics, …), lesion counts and adverse 
event(s) will only be summarized descriptively, on appropriate population. 
9.2 SAMPLE SIZE DETERMINATION 
 Historical data and assumptions 9.2.1
No previous study exists associating Ivermectin 1% cream and Doxycycline MR. Therefore, this 
sample size was calculated using the results (% change from baseline in inflammatory lesion 
counts at Week 12) of previous studies on subjects treated with: 
 Ivermectin 1% cream alone, which showed a standard deviation (SD) between 25.4% to 
39.9% (with a mean around 35%).  
 Doxycycline MR alone, which showed a minimum difference of 26% at Week 12, vs. Placebo 
Using this historical data, we can assume that the difference between the association 
(Ivermectin + Doxycycline MR) and Ivermectin will be at least of 15% with a SD of 35%. 
 
     Sample size calculation 9.2.[ADDRESS_403651] 15% difference at Week 12, with 90% power. To allow a 15% 
rate of subjects excluded from analysis (drop out, lost to foll ow-up, etc.) at Week 12, 135 
subjects per group (270 in total) are to be enrolled. 
  
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.113322  
version Final dated 10-FEB-2017 
Page 78 of 106 CONFIDENTIAL 
 
10. TRAINING / MONITORING / DATA MANAGEMENT / QUALITY ASSURANCE 
A contract research organization (CRO) will be responsible for monitoring the clinical trial and 
the sponsor may perform co-monitoring visits at selected sites. 
10.1 PERSONNEL TRAINING  
Clinical Research Associates (CRA) will be trained prior to clinical trial initiation. During this 
training, an overview of the disease of interest and treatment will be presented. Specific 
monitoring guidelines and procedures to be followed during monitoring visits will be discussed. 
Initiation visits will be conducted with all Principal Investigators and site teams. During these 
visits, an extensive review and discussion of the protocol, procedures and CRF will be 
conducted. Evaluation scales will also be reviewed. 
A trial reference monitoring manual will be provided to each CRA as an additional reference tool.  
An eCRF completion guideline will be provided to each CRA and site. These guidelines will 
contain instructions on how to fill-in the eCRF with some examples in order to standardize the 
eCRF completion as much as possible. 
A trial reference manual will be provided to each site as an additional reference tool. These 
guidelines will contain key CRO and Sponsor contacts and phone numbers and specific 
instructions for site in order to standardize as much as possible the assessments performed 
during the clinical trial.  
10.[ADDRESS_403652] of the clinical trial will be closely monitored by [CONTACT_327069]/ GALDERMA 
R&D to verify the adherence to the clinical trial protocol, ICH-GCP regulations, applicable SOPs, 
guidelines, and all local regulations.  
The investigator will allow representatives of GALDERMA R&D/CRO to have direct access to all 
clinical trial records, CRFs, corresponding subject medical records, investigational product 
dispensing records and investigational product storage area, site facilities and any other 
documents considered as source documentation. 
The investigator also agrees to assist the GALDERMA R&D/  CRO  representatives, if required. 
10.3 DATA MANAGEMENT  
A CRO will be responsible for data management in connection with the sponsor ’s data manager. 
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.113322  
version Final dated 10-FEB-2017 
Page 79 of 106 CONFIDENTIAL 
All data management procedures will be detailed in the Data Management Plan (DMP).  
The DMP will describe the Clinical Data Management System (CDMS) that will be used to 
collect and validate data. Computerized edit checks and review processes will be performed on 
an ongoing basis as outlined in the DMP until all data discrepancies are resolved. 
After all data discrepancies are resolved, coding is approved, and subject evaluability has been 
determined, the data will be exported to SAS datasets and will be locked. 
After unblinding, the locked SAS database will be used to generate subject listings, tabulations 
and analyses.  
The data may be audited by [CONTACT_23638]/or CRO Quality Assurance department before or 
after the first statistical analysis results on the primary criteria. 
10.4 QUALITY ASSURANCE / AUDIT / INSPECTION  
The clinical trial will be conducted under the sponsorship of GALDERMA R&D in compliance 
with all appropriate local and local regulations as well as ICH guidelines and in accordance with 
the SOPs for clinical trial conduct and monitoring from GALDERMA R&D and/or the Contract 
Research Organization (CRO). 
Audits of clinical trial sites may be conducted by [CONTACT_1034]/CRO representatives, and 
inspection may be performed by [CONTACT_154504]/ECs before, during, 
or after the clinical trial.   
The investigator will allow and assist the CRO/Sponsor ’s representatives, IRBs/ECs and any 
regulatory agency to have direct access to all requested clinical trial-related records. 
For the audits performed by, or on behalf of, GALDERMA R&D  auditors, audit certificate(s) will 
be provided by [CONTACT_154505]. 
 
11. ETHICS AND GENERAL CLINICAL TRIAL CONDUCT CONSIDERATIO NS 
11.[ADDRESS_403653] (IRB)  OR ETHICS COMMITTEE (EC) 
This clinical trial protocol will be reviewed and approved by [CONTACT_1202]/ECs prior to clinical trial 
initiation. 
This protocol may be modified at any time for ethical, medical or scientific reasons. Such 
modifications will be documented by a clinical protocol amendment and, if deemed necessary, 
an amended protocol will be issued. 
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.113322  
version Final dated 10-FEB-2017 
Page 80 of 106 CONFIDENTIAL 
Before implementation, the amendment should be submitted and approved by [CONTACT_327070]/ECs and, if required by [CONTACT_121352](ies). 
No amendment will be required for modification(s) due to a change in logistical or administrative 
aspects of the clinical trial (e.g., change in monitors, change of telephone numbers). In such a 
case, the appropriate institution(s) and/or person(s) will be directly notified of the changes. 
11.[ADDRESS_403654] OF THE CLINICAL TRIAL  
This clinical trial will be conducted in accordance with the ethical principles originating from the 
Declaration of HELSINKI declaration (1964) and subsequent amendments, the International 
Conference on Harmonization (ICH), Good Clinical Practice (GCP) and in compliance with local 
regulatory requirements. 
11.[ADDRESS_403655] INFORMATION SHEET / INFORMED CONSENT  
All subjects who participate in this trial will have to be fully informed about the clinical trial in 
accordance with the applicable regulations and GCP guidelines and in accordance with local 
legal requirements.  
Prior to any clinical trial procedures, the subject will sign and date the informed consent form(s) 
which is written in the local language. A copy of the signed and dated form(s) will be given to the 
subject. The investigator is responsible for maintaining each subject ’s consent form(s) in the 
investigator ’s site file (ISF) and providing each subject with a copy of the consent form. 
The informed consent form including photograph release form approved by [CONTACT_2717]/EC will be 
fully explained to the subject, when applicable .  
11.4 CONTRACTUAL REQUIREMENTS  
A contractual agreement will be signed between the CRO/Sponsor and each 
Investigator/Institution.  This document will contain supplementary information, including 
financial terms, confidentiality, the clinical trial schedule, third party responsibility, and 
publication rights. 
11.[ADDRESS_403656] ’s source documents and in the eCRF, the 
product dispensation logs, the subj ects’ diaries and questionnaires provided by [CONTACT_154500] 
R&D.  
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.113322  
version Final dated 10-FEB-2017 
Page 81 of 106 CONFIDENTIAL 
All data recorded in the documents described above should be recorded completely, promptly, 
and legibly using black ink.  
The appropriate pages will be collected upon clinical trial completion or at any other time 
specified by [CONTACT_231801]/sponsor.  
A complete set of copi[INVESTIGATOR_327010] . 
 Source documentation 11.5.[ADDRESS_403657] keep accurate separate records (other than the eCRF) of all subjects ’ visits, 
and all procedures done, being sure to include all pertinent clinical trial related information from 
which CRF data will be recorded.  
A statement should be made on subject ’s medical notes indicating that the subject has been 
enrolled in GALDERMA R&D protocol RD.03.SPR .[ADDRESS_403658] be thoroughly documented. 
Results of any diagnostic tests conducted during the clinical trial will be included in the source 
documentation. 
Telephone conversations with the subjects and/or CRO/ GALDERMA R&D concerning the 
clinical trial may be recorded and kept on file. 
 Archives 11.5.3
All pertinent data, samples, photos, questionnaires, correspondence, original or amended 
protocol, all reports and all other material relating to the clinical trial will be maintained securely 
in GALDERMA R&D / Investigator/Institution archives for the legally-required duration of 
archivin g. 
If the investigator retires, relocates, or for any other reason withdraws from the responsibility of 
keepi[INVESTIGATOR_327011], custody must be transferred to a person who will accept the 
responsibility. The sponsor must be notified in writing of the name [CONTACT_66903]. 
11.[ADDRESS_403659] party coverage of CRO/ GALDERMA R&D will be provided upon 
request.  
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.[ADDRESS_403660] grading system for rosacea: report of the National 
Rosacea Society Expert Committee on the classification and staging of rosacea. J Am Acad 
Dermatol. 2004 Jun; 50(6):907- 12. 
2. Tan J et al. 2016 Updating the diagnosis, classification and assessment of rosacea: 
Recommendations from the global ROSacea COnsensus (ROSCO) panel. 
3. Chosidow O, Cribier B. Epi[INVESTIGATOR_327012]: updated data. Ann Dermatol Venereol. 
2011 Nov;[ADDRESS_403661] 3:S179- 83. 
4. Tan J, Berg M. Rosacea: current state of epi[INVESTIGATOR_623]. J Am Acad Dermatol. 2013;69([ADDRESS_403662] 1):S27-35. 
5. Culp B, Scheinfeld N. Rosacea: a review. P T. 2009 Jan;34(1):38-45. 
6.  Korting HC, Schöllmann C. Current topi[INVESTIGATOR_327013]. J Eur Acad Dermatol Venereol. 2009 Aug;23(8):876- 82. 
7. Powell FC. Clinical practice. Rosacea. N Engl J Med. 2005;352(8):793-803. 
8. A. Taieb, A. Khemis, T. Ruzicka, W. Baranska-Rybak, J. Berth-Jones, J. Schauber, P. 
Briantais, J. Jacovella, T. Passeron on behalf of the Ivermectin Phase III Study Group. 
Maintenance of remission following successful treatment of papulopustular rosacea with 
ivermectin 1% cream vs. metronid azole 0.75% cream: 36-week extension of the ATTRACT 
randomized study. JEADV 2016, 30, 829 –836 
9. David A. Jones. Rosacea, Reactive Oxygen Species, and Azelaic Acid. J Clin Aesthet 
Dermatol. 2009 Jan; 2(1): 26 –30. 
10. Martin Steinhoff, Marc Vocanson, Johannes J Voegel, Feriel Hacini-Rachinel and Gregor 
Schäfer Topi[INVESTIGATOR_98709] 10 mg/g and Oral Doxycycline 40 mg Modified-Release: Current 
Evidence on the Complementary Use of Anti-Inflammatory Rosacea Treatments. Adv Ther. 
2016; 33(9): 1481 –1501. 
11. J Mark Jackson, Melissa Knuckles, John Paul Minni, Sandra Marchese Johnson, and Kevin 
Tate Belasco. The role of brimonidine tartrate gel in the treatment of rosacea. Clin Cosmet 
Investig Dermatol. 2015; 8: 529 –[ADDRESS_403663] GH, James WD. Rosacea: II. Therapy. J Am Acad Dermatol.[ADDRESS_403664];51(4):499-512. 
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.113322  
version Final dated 10-FEB-2017 
Page 83 of 106 CONFIDENTIAL 
13. Martin Schaller, Thomas Dirschka, Lajos Kemény, Philippe Briantais, and Jean Jacovella. 
Superior Efficacy with Ivermectin 1% Cream Compared to Metronidazole 0.75% Cream 
Contributes to a Better Quality of Life in Patients with Severe Papulopustular Rosacea: A 
Subanalysis of the Randomized, Investigator-Blinded ATTRACT Study. Dermatol The r 
(Heidelb). 2016 Sep; 6(3): 427 –436. 
14. Sanchez J, Somolinos AL, Almodóvar PI, Webster G, Bradshaw M, Powala C. A 
randomized, double-blind, placebo-controlled trial of the combined effect of doxycycline 
hyclate 20-mg tablets and metronidazole 0.75% topi[INVESTIGATOR_327014]. J 
Am Acad Dermatol. 2005 Nov;53(5):791-7.  
15. Asai Y, Tan J, Baibergenova A, Barankin B, Cochrane CL, Humphrey S, Lynde CW, 
Marcoux D, Poulin Y, Rivers JK, Sapi[INVESTIGATOR_327015] M, Sibbald RG, Toole J, Ulmer M, Zip C. 
Canadian Clinical Practice Guidelines for Rosacea. J Cutan Med Surg. 2016 Sep;20(5):432-
45. 
16. Revicki DA, Willian MK, Menter A, Gordon KB, Kimball AB, Leonardi CL, Langley RG, Kimel 
M, Okun M: Impact of adalimumab treatment on patient-reported outcomes: results from a 
Phase III clinical trial in patients with moderate to severe plaque psoriasis. J Dermatolog 
Treat 2007, 18:341- 350 
17. Spi[INVESTIGATOR_327004] R:  Patch Testing for Contact [CONTACT_327071].  The Open 
Allergy Journal, 2008, 1, 42- 51 
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.113322  
version Final dated 10-FEB-2017 
Page 84 of 106 CONFIDENTIAL 
13. ATTACHMENTS 
13.1 ATTACHMENT#  1:  
DERMATOLOGY LIFE QUALITY INDEX QUESTIONNAIRE (DLQI)  
At the beginning and end of the trial, subjects will answer the 10-item DLQI questionnaire. 
 
The aim of this questionnaire is to measure how much your skin problem has affected your life 
OVER THE LAST WEEK. Please tick  one box for each question 
 
1. Over the last week, how itchy, sore,  
 painful  or stinging  has your skin be en?  Very much  
        A lot   
        A little   
        Not at all  
 
2. Over the last week, how embarrassed  or  
 self-conscious  have you been because of  
 your skin?  Very much  
        A lot   
        A little   
        Not at all  
3. Over the last week, how much has your  
 skin interfered with you going shoppi[INVESTIGATOR_327016]  
 looking after your home or garden ?  A lot   
        A little   
        Not at all  
Not relevant  
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.[ADDRESS_403665] week, how much has your  
 skin influenced the clothes  you wear?  Very much  
        A lot   
        A little   
        Not at all  
Not relevant  
5. Over the last week, how much has your  
 skin affected any social  or leisure  activities? Very much  
        A lot   
        A little   
        Not at all  
Not relevant  
 
 
6. Over the last week, how much has your  
 skin made it difficult for you to do any sport ? Very much  
        A lot   
        A little   
        Not at all  
Not relevant  
 
7.  Over the last week, has your skin prevented  
 you from working  or studying ?   Yes   
        No   
Not relevant  
 If "No", over the last week how much has  
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.113322  
version Final dated 10-FEB-2017 
Page 86 of 106 CONFIDENTIAL 
 your skin been a problem at work   
or studying?      A lot   
        A little   
        Not at all  
 
8. Over the last week, how much has your    
 skin created problems with your partner  or Very much  
  any of your close friends  or relatives ?  A lot   
        A little   
        Not at all  
Not relevant  
 
9. Over the last week, how much has your  
 skin caused any sexual difficulties ?  Very much  
        A lot   
        A little   
        Not at all  
Not relevant  
 
10. Over the last week, how much of a   Very much  
 problem has the treatment  for your skin  A lot   
 been, for example by [CONTACT_327072]  A little   
 messy, or by [CONTACT_78469]?   Not at all  
        Not relevant  
 
Please check you have answered EVERY question. Thank you. 
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.113322  
version Final dated 10-FEB-2017 
Page 87 of 106 CONFIDENTIAL 
®AY Finlay, GK Khan, April [ADDRESS_403666] not be copi[INVESTIGATOR_327017]. 
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.113322  
version Final dated 10-FEB-2017 
Page 88 of 106 CONFIDENTIAL 
13.2 ATTACHMENT#  2:   EQ-5D-5L QUESTIONNAIRE 
Under each heading, please check the ONE box that best describes your health TODAY.  
MOBILITY  
I have no problems walking   
I have slight problems walking   
I have moderate problems walking   
I have severe problems walking   
I am unable to walk   
SELF -CARE   
I have no problems washing or dressing myself   
I have slight problems washing or dressing myself   
I have moderate problems washing or dressing myself   
I have severe problems washing or dressing myself   
I am unable to wash or dress myself   
USUAL ACTIVITIES ( e.g. work, study, housework, family or leisure 
activities)   
I have no problems doing my usual activities   
I have slight problems doing my usual activities   
I have moderate problems doing my usual activities   
I have severe problems doing my usual activities   
I am unable to do my usual activities   
PAIN / DISCOMFORT   
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.[ADDRESS_403667] no pain or discomfort   
I have slight pain or discomfort   
I have moderate pain or discomfort   
I have severe pain or discomfort   
I have extreme pain or discomfort   
ANXIETY / DEPRESSION   
I am not anxious or depressed   
I am slightly anxious or depressed   
I am moderately anxious or depressed   
I am severely anxious or depressed   
I am extremely anxious or depressed   
 
 
  
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.113322  
version Final dated 10-FEB-2017 
Page 90 of 106 CONFIDENTIAL 
10 
0 20 30 40 50 60 80 
70 90 100 
5 15 25 35 45 55 75 
65 85 95  
 
 We would like to know how good or bad your health is TODAY.  
 This scale is numbered from 0 to 100.  
 [ADDRESS_403668]  health you can imagine.  
 Mark an X on the scale to indicate how your health is TODAY.  
 Now, please write the number you marked on the scale in the box below.  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 The best health you 
can imagine  
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.[ADDRESS_403669] health 
you can imagine   
 
 
 
 
 
 
 
 
 
 
[LOCATION_003] (English) © 2009 EuroQol Group EQ-5D™ is a trade mark of the EuroQol Grou p 
 
  YOUR HEALTH TODAY  = 
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.113322  
version Final dated 10-FEB-2017 
Page 92 of 106 CONFIDENTIAL 
13.3 ATTACHMENT#  3:    
Work Productivity and Activity Impairment Questionnaire: 
General Health V2.0 (WPAI:GH)  
modified for Rosacea . 
 
 
 
The following questions ask about the effect of your rosacea on your ability to work and perform 
regular activities. Please fill in the blanks or circle a number, as indicated. 
 
1. Are you currently employed (working for pay)?  ____  NO ____  YES 
 If NO, c heck “NO” and skip to question 6.  
The next questions are about the past seven days , not including today. 
 
2. During the past seven days, how many hours did you miss from work because of your 
rosacea ? Include hours you missed on sick days, times you went in late, left early, etc., 
because of your rosacea. Do not include time you missed to participate in this study. 
_____HOURS 
 
3. During the past seven days, how many hours did you miss from work because of any other 
reason, such as vacation, holidays, time off to participate in this study? 
_____HOURS 
 
4. During the past seven days, how many hours did you actually work? 
_____HOURS (If “0”, skip to question 6.) 
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.[ADDRESS_403670] your productivity while you 
were working ?  
 
Think about days you were limited in the amount or kind of work you could do, days you 
accomplished less than you would like, or days you could not do your work as carefully as 
usual. If rosacea affected your work only a little, choose a low number. Choose a high 
number if rosacea affected your work a great deal.  
 
Consider only how much rosacea affected  
productivity while you were working. 
Rosacea had no 
effect on my 
work             Rosacea 
completely 
prevented me 
from working  [ADDRESS_403671] your ability to do your 
regular daily activities, other than work at a job?  
 
By [CONTACT_43681], we mean the usual activities you do, such as work around the house, 
shoppi[INVESTIGATOR_007], childcare, exercising, studying, etc. Think about times you were limited in the 
amount or kind of activities you could do and times you accomplished less than you would 
like. If rosacea affected your activities only a little, choose a low number. Choose a high 
number if rosacea affected your activities a great deal.  
 
Consider only how much rosacea affected your ability  
to do your regular daily activities, other than work at a job. 
Rosacea had no            Rosacea 
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.[ADDRESS_403672] A NUMBER 
 
  
WPAI:GH   V2.0 (US English)   modified for Rosacea    
Reilly MC, Zbrozek AS, Dukes E: The validity and reproducibility of a work productivity and activity impairment measure.  PharmacoEconomics 
1993; 4(5):353-365. 
13.4 ATTACHMENT#  4:   SUBJECT’S  SATISFACTION  QUESTIONNAIRE  
The Subject’s Satisfaction Survey will be completed at Week 12 / Early Termination by [CONTACT_327073]. 
A- Questions about study drugs (capsules and cream) 
1. How satisfied are you with the time the study regimen took to work? 
 Very satisfied 
 Satisfied 
 Somewhat satisfied 
 Not satisfied 
 
2. How satisfied are you with the improvement of your facial lesions since starting the study 
regimen? 
 Very satisfied 
 Satisfied 
 Somewhat satisfied 
 Not satisfied 
 
3. How satisfied are you with the improvement of your facial redness since starting the 
study regimen? 
 Very satisfied 
 Satisfied 
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.113322  
version Final dated 10-FEB-2017 
Page 95 of 106 CONFIDENTIAL 
 Somewhat satisfied 
 Not satisfied 
 
4. How satisfied are you with the improvement of your ocular symptoms since starting the 
study regimen? 
 Very satisfied 
 Satisfied 
 Somewhat satisfied 
 Not satisfied 
 Not applicable 
 
 
5. How satisfied are you with the improvement of your flushing epi[INVESTIGATOR_327018]? 
 Very satisfied 
 Satisfied 
 Somewhat satisfied 
 Not satisfied 
 Not applicable 
6. How bothered are you by [CONTACT_327074]? 
 Not bother at all 
 Bothered a little 
 Bothered somewhat 
 Bothered a great deal 
 
7. How does your face look since starting the study regimen? 
 A lot better 
 A little better 
 No change 
 Worse 
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.113322  
version Final dated 10-FEB-2017 
Page 96 of 106 CONFIDENTIAL 
  
  
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.113322  
version Final dated 10-FEB-2017 
Page 97 of 106 CONFIDENTIAL 
8. How do feel since starting the study regimen? 
 A lot better 
 A little better 
 No change 
 Worse 
 
9. The study  regimen was  easy to incorporate in your daily routine 
 Strongly agree 
 Agree  
 Disagree 
 Strongly disagree 
 
10. Would you consider using the study regimen again?  
 Yes  
 No 
 
11. How satisfied are you overall with the study regimen? 
 Very satisfied 
 Satisfied 
 Somewhat satisfied 
 Not satisfied 
  
12.     How did you find the study regimen compared to the last treatment(s) you received prior 
starting the study? 
 
 A lot better 
       Better 
 Similar 
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.113322  
version Final dated 10-FEB-2017 
Page 98 of 106 CONFIDENTIAL 
 Worse 
 Never treated with a previous treatment
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.113322  
version Final dated 10-FEB-2017 
Page 99 of 106 CONFIDENTIAL 
B- Questions about both provided skin care products Cleanser and Moisturizer 
  
1. Both skin care products were easy to incorporate into a daily routine: 
 Strongly agree 
 Agree  
 Neither agree or disagree  
 Disagree 
 Strongly disagree 
 
2. I would recommend  both skin care products to my family or friends: 
 Strongly agree 
 Agree  
 Neither agree or disagree  
 Disagree 
 Strongly disagree 
 
3. I felt - both skin care products helped my skin look healthier 
 Strongly agree 
 Agree  
 Neither agree or disagree  
 Disagree 
 Strongly disagree 
 
4. Using both skin care products for rosacea, made me feel more confident  
 Strongly agree 
 Agree  
 Neither agree or disagree  
 Disagree 
 Strongly disagree 
 
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.113322  
version Final dated 10-FEB-2017 
Page 100 of 106 CONFIDENTIAL 
 
 
 
 
5. I felt - both skin care products made me feel more confident with my skin appearance 
 Strongly agree 
 Agree  
 Neither agree or disagree  
 Disagree 
 Strongly disagree 
 
6. I felt – both skin care products helped make a positive difference in the appearance of 
my skin 
 Strongly agree 
 Agree  
 Neither agree or disagree  
 Disagree 
 Strongly disagree 
 
7. I would keep using both skin care products 
 Strongly agree 
 Agree  
 Neither agree or disagree  
 Disagree 
 Strongly disagree 
  
8.  Both skin care products make my skin more hydrated 
 Strongly agree 
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.113322  
version Final dated 10-FEB-2017 
Page 101 of 106 CONFIDENTIAL 
 Agree  
 Neither agree or disagree  
 Disagree 
 Strongly disagree 
  
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.113322  
version Final dated 10-FEB-2017 
Page 102 of 106 CONFIDENTIAL 
9.  Both skin care products improved the texture of my skin  
 Strongly agree 
 Agree  
 Neither agree or disagree  
 Disagree 
 Strongly disagree 
 
10. Both skin care products are pleasant to use  
 Strongly agree 
 Agree  
 Neither agree or disagree  
 Disagree 
 Strongly disagree 
  
  
  
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.[ADDRESS_403673] cleanser 
1. The Cleanser left my skin with a clean healthy feeling:  
 Strongly agree 
 Agree  
 Neither agree or disagree  
 Disagree 
 Strongly disagree 
 
2. The Cleanser provided deep cleansing without strippi[INVESTIGATOR_327019]’s moisture:  
 Strongly agree 
 Agree  
 Neither agree or disagree  
 Disagree 
 Strongly disagree 
 
3. The Cleanser rinsed off easily:  
 Strongly agree 
 Agree  
 Neither agree or disagree  
 Disagree 
 Strongly disagree 
 
4. The Cleanser did not make my skin feel tight or dry:  
 Strongly agree 
 Agree  
 Neither agree or disagree  
 Disagree 
 Strongly disagree 
  
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.113322  
version Final dated 10-FEB-2017 
Page 104 of 106 CONFIDENTIAL 
  
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.[ADDRESS_403674] Moisturizer  
1. The Moisturizer made my skin feel soft and smooth:  
 Strongly agree 
 Agree  
 Neither agree or disagree  
 Disagree 
 Strongly disagree 
 
2. The Moisturizer improved my skin’s texture:  
 Strongly agree 
 Agree  
 Neither agree or disagree  
 Disagree 
 Strongly disagree 
 
3. The Moisturizer left my skin feeling hydrated and protected:  
 Strongly agree 
 Agree  
 Neither agree or disagree  
 Disagree 
 Strongly disagree 
 
4. The Moisturizer provided a comforting sensation on the skin:  
 Strongly agree 
 Agree  
 Neither agree or disagree  
 Disagree 
 Strongly disagree 
 
GALDERMA RESEARCH & DEVELOPMENT 
Protocol N° RD.03.SPR.113322  
version Final dated 10-FEB-2017 
Page 106 of 106 CONFIDENTIAL 
 